ELSEVIER

Journal of the Neurological Sciences 194 (2002) 93–106

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

Cumulative Author Index (2002) Volumes 184–194

Aadland, S., see Aarskog, N.K. (188) 21
Aarskog, N.K., Aadland, S., Gjerde, I.O. and Vedeler, C.A.
Molecular genetic analysis of Charcot–Marie–Tooth 1A duplication in Norwegian patients by quantitative photostimulated luminescence imaging (188) 21
Aasly, J., see Øren, A. (186) 31
Abe, K., see Hanyu, H. (188) 79
Abe, K., see Murakami, T. (189) 45
Abe, K., see Manabe, Y. (193) 13
Adachi, Y., see Mori, M. (185) 43
Adèr, H.J., see Kalkers, N.F. (184) 155
Adèr, H.J., see Kalkers, N.F. (187) 111
Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials, Apfel, S.C., Asbury, A.K., Bril, V., Burns, T.M., Campbell, J.N., Chalk, C.H., Dyck, P.J., Dyck, P.J.B., Feldman, E.L., Fields, H.L., Grant, I.A., Griffin, J.W., Klein, C.J., Lindblom, U., Litchy, W.J., Low, P.A., Melanson, M., Mendell, J.R., Merren, M.D. and O'Brien, P.C.
Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials (189) 3
Aguilera, I., García-Lozano, J.-R., Muñoz, A., Arenas, J., Campos, Y., Chinchón, I., Roldán, A.-N. and Bautista, J.
Mitochondrial DNA point mutation in the COI gene in a patient with McArdle's disease (192) 81
Aizawa, H., see Katayama, T. (193) 37
Akhmedova, S.N., Yakimovsky, A.K. and Schwartz, E.I.
Paraoxonase 1 Met–Leu 54 polymorphism is associated with Parkinson's disease (184) 179
Akiguchi, I., see Mizutani, K. (188) 9
Akiyama, H., see Togo, T. (184) 71
Al-Khalaf, A., see Grau, A.J. (192) 41
Albert, S.M., Murphy, P.L., Del Bene, M., Rowland, L.P. and Mitsumoto, H.
Incidence and predictors of PEG placement in ALS/MND (191) 115
Alcázar, A., see Cid, C. (193) 103
Alcina, A., see Fedetz, M. (190) 69
Alexander, G.E., see Caselli, R.J. (189) 93
Alexander, G.E., see Hampel, H. (194) 15
Alexander, G.M., see Deitch, J.S. (193) 117
Alexander, M., see Thomas, S.V. (188) 73
Álvarez-Cermeño, J.C., see Cid, C. (193) 103
Amaike, M., see Namekawa, M. (185) 63
Amaike, M., see Shimazaki, H. (185) 101
Amari, M., see Hayashi, S. (188) 3
Amoroso, A., see Masè, G. (191) 11
Anand, A., see Murgod, U.A. (190) 73
Andersen, P.M., Grönberg, H., Franzen, L. and Funegård, U.
External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis (191) 111
Andersson, T., see Press, R. (190) 41
Ando, Y., see Namekawa, M. (187) 103
Apfel, S.C., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Arahata, K., see Nakagawa, M. (184) 15
Arenas, J., see Aguilera, I. (192) 81
Arimura, K., see Nakagawa, M. (185) 31
Arimura, K., see Matsuyama, W. (186) 75
Arndt, C., see De Seze, J. (188) 37
Asano, M., see Matsuda, M. (184) 189
Asano, T., see Hanyu, H. (188) 79
Asbury, A.K., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Athanasiou, A., see Perunovic, B. (185) 55
Auchus, A.P., see Tan, E.K. (190) 95
Auchus, A.P., see Tan, E.K. (193) 53
Augustin, A., see Schmidt, S. (187) 49
Avolio, C., Ruggieri, M., Cafforio, P., Giuliani, F., Silvestris, F., Dammacco, F., Livrea, P. and Trojano, M.
LFA-1 expression on $CD4^+CD45RO^+$ peripheral blood T-lymphocytes in RR MS: effects induced by rIFNβ-1a (186) 65
Ayachi, M., see De Seze, J. (188) 37

Bakshi, R., Dmochowski, J., Shaikh, Z.A. and Jacobs, L.
Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients (185) 19
Balestrieri, G., see Monastero, R. (184) 33
Ball, L.J., Willis, A., Beukelman, D.R. and Pattee, G.L.
A protocol for identification of early bulbar signs in Amyotrophic Lateral Sclerosis (191) 43
Balzarini, C., see Mazzini, L. (191) 139
Barbero, P., see Durelli, L. (193) 17
Barbieri, C.J., see Caselli, R.J. (189) 93
Bardoni, A., see Sironi, M. (186) 51
Barkhof, F., see Kalkers, N.F. (184) 155
Barkhof, F., see Kalkers, N.F. (187) 111
Barlas, Ö., see Yılmaz, M. (186) 27
Barohn, R., see Miller, R.G. (191) 127
Barohn, R.J., see Jackson, C.E. (191) 75
Basile, A.M., see Di Carlo, A. (188) 85
Bautista, J., see Aguilera, I. (192) 81
Bayazıt, Y.A., see Yılmaz, M. (186) 27
Bayazıt, Y.A., see Erdal, M.E. (188) 99
Bayazit, Y.A., see Yilmaz, M. (184) 139
Bayer, W., see Hampel, H. (194) 15
Becher, H., see Grau, A.J. (186) 1
Becher, H., see Grau, A.J. (192) 41
Behari, M., Srivastava, A.K., Das, R.R. and Pandey, R.M.
Risk factors of Parkinson's disease in Indian patients (190) 49
Belden, D.S., see Sanjak, M. (191) 55
Bendotti, C., Calvaresi, N., Chiveri, L., Prelle, A., Moggio, M., Braga, M., Silani, V. and De Biasi, S.
Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity (191) 25
Benna, P., see Montalenti, E. (184) 65
Bensimon, G., see Spreux-Varoquaux, O. (193) 73

PII: S0022-510X(02)00011-4

Berciano, J., Mateo, I., De Pablos, C., Polo, J.M. and Combarros, O.
Friedreich ataxia with minimal GAA expansion presenting as adult-onset spastic ataxia (194) 75
Bergamaschi, R., Berzuini, C., Romani, A. and Cosi, V.
Predicting secondary progression in relapsing–remitting multiple sclerosis: a Bayesian analysis (189) 13
Bergamasco, B., see Montalenti, E. (184) 65
Bergamasco, B., see Perozzo, P. (192) 9
Bergamasco, B., see Durelli, L. (193) 17
Bergmann, C., see Senderek, J. (192) 49
Bertorini, T.E., see Narayanaswami, P. (184) 11
Bertram, M., see Grau, A.J. (192) 41
Berzuini, C., see Bergamaschi, R. (189) 13
Bettini, P., see Monastero, R. (184) 33
Beukelman, D.R., see Ball, L.J. (191) 43
Bhalla, A., see Hajat, C. (190) 79
Bianchi, S., see Inglese, M. (188) 33
Biondi, E., see Di Carlo, A. (188) 85
Birnbaum, M., see Drory, V.E. (190) 17
Bisser, S., Lejon, V., Preux, P.M., Bouteille, B., Stanghellini, A., Jauberteau, M.O., Büscher, P. and Dumas, M.
Blood–cerebrospinal fluid barrier and intrathecal immunoglobulins compared to field diagnosis of central nervous system involvement in sleeping sickness (193) 127
Block, W., see Pohl, C. (190) 21
Blumhardt, L.D., see Lin, X. (189) 99
Bogousslavsky, J., see De Freitas, G.R. (193) 43
Bokde, A.L.W., Teipel, S.J., Zebuhr, Y., Leinsinger, G., Gootjes, L., Schwarz, R., Buerger, K., Scheltens, P., Moeller, H.-J. and Hampel, H.
A new rapid landmark-based regional MRI segmentation method of the brain (194) 35
Bonacchi, M., see Di Carlo, A. (188) 85
Bonfigli, L., see Masè, G. (191) 11
Boniotto, M., see Masè, G. (191) 11
Bontrop, R., see Mancardi, G. (184) 41
Borasio, G.D., see Neudert, C. (191) 103
Borasio, G.D., see Wasner, M. (191) 151
Bortolomasi, M., see Manganotti, P. (184) 27
Bouche, P., see Le Forestier, N. (185) 95
Bouteille, B., see Bisser, S. (193) 127
Boyden, J.W., see Greenlee, J.E. (184) 131
Bracco, L., see Di Carlo, A. (188) 85
Bradley, W., see Miller, R.G. (191) 127
Bradley, W.G., see Mowzoon, N. (185) 119
Braga, M., see Bendotti, C. (191) 25
Brahmachari, S.K., see Murgod, U.A. (190) 73
Brambilla, D., see Montirosso, R. (194) 3
Brandt, T., see Grau, A.J. (186) 1
Brashear, H.R., see Greenlee, J.E. (184) 131
Brenner, M., see Sairanen, T.R. (186) 87
Bresolin, N., see Sironi, M. (186) 51
Bresolin, N., see Montirosso, R. (194) 3
Brierley, C.M.H., see Hickman, S.J. (187) 35
Bril, V., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Brinkmann, J., see Sanjak, M. (191) 55
Brok, H., see Mancardi, G. (184) 41
Bromberg, M.B., Fries, T.J., Forshew, D.A. and Tandan, R.
Electrophysiologic endpoint measures in a multicenter ALS drug trial (184) 51
Brooks, B.R., see Sanjak, M. (191) 55
Brossa, P.C., see Durelli, L. (193) 17
Bryan, W., see Miller, R.G. (191) 127
Bryan, W.W., see Jackson, C.E. (191) 75
Buerger, K., see Bokde, A.L.W. (194) 35
Bufler, J., see Krampfl, K. (191) 19
Buggle, F., see Grau, A.J. (186) 1
Buggle, F., see Grau, A.J. (192) 41
Bughin, M., see De Seze, J. (188) 37
Burchardt, F., see Lee, J.N. (191) 79
Burns, T.M., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Burrell, A., see Kiebert, G.M. (191) 87
Büscher, P., see Bisser, S. (193) 127

Cafforio, P., see Avolio, C. (186) 65
Cagliani, R., see Sironi, M. (186) 51
Caimi, G., Canino, B., Ferrara, F., Montana, M., Musso, M., Porretto, F., Carollo, C., Catania, A. and Lo Presti, R.
Granulocyte integrins before and after activation in acute ischaemic stroke (186) 23
Caligari, M., see Mazzini, L. (191) 139
Calvaresi, N., see Bendotti, C. (191) 25
Camarda, R., see Monastero, R. (184) 33
Campanella, G., see Perretti, A. (192) 35
Campbell, J.N., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Campos, Y., see Aguilera, I. (192) 81
Canino, B., see Caimi, G. (186) 23
Capello, E., see Mancardi, G. (184) 41
Capobianco, A., see Comoletti, D. (192) 61
Carbonetto, F., see Di Carlo, A. (188) 85
Carollo, C., see Caimi, G. (186) 23
Carpén, O., see Sairanen, T.R. (186) 87
Carraro, N., see Masè, G. (191) 11
Caselli, R.J., Osborne, D., Reiman, E.M., Hentz, J.G., Barbieri, C.J., Saunders, A.M., Hardy, J., Graff-Radford, N.R., Hall, G.R. and Alexander, G.E.
Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study (189) 93
Castelli, L., see Perozzo, P. (192) 9
Çataloluk, O., see Yılmaz, M. (186) 27
Catania, A., see Caimi, G. (186) 23
Cattaneo, R., see Monastero, R. (184) 33
Cazzato, G., see Zorzon, M. (187) 1
Cazzato, G., see Masè, G. (191) 11
Chalk, C.H., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Chan, L.L., see Tan, E.K. (193) 53
Chang, C.-P., see Tsai, C.-H. (190) 35
Chang, J.-G., see Tsai, C.-H. (190) 35
Changes, E.T.F.A.-R.W.M., see De Reuck, J. (193) 1
Chapman, J., see Wang, N. (184) 183
Chapman, J., see Drory, V.E. (190) 17
Chen, C.-M., see Tsai, C.-H. (190) 35
Chen, J., Li, Y., Wang, L., Lu, M., Zhang, X. and Chopp, M.
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats (189) 49
Chen, J., see Li, Y. (193) 137
Chida, K., see Kikuchi, A. (193) 29
Chihara, K., see Yoshihara, T. (184) 149
Chinchón, I., see Aguilera, I. (192) 81
Chiò, A., Silani, V. and Italian ALS Study Group
Amyotrophic lateral sclerosis care in Italy: a nationwide study in neurological centers (191) 145
Chiveri, L., see Bendotti, C. (191) 25
Choksi, R., see Lopate, G. (188) 67
Chopp, M., see Chen, J. (189) 49
Chopp, M., see Li, Y. (193) 137
Christen-Zäch, S., see De Freitas, G.R. (193) 43
Chu, K., Kang, D.-W., Kim, D.-E. and Roh, J.-K.
Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy (185) 27

Cid, C., Alcázar, A., Regidor, I., Masjuan, J., Salinas, M. and Álvarez-Cermeño, J.C.
Neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients correlates with hypointense lesions on T1 magnetic resonance imaging (193) 103
Clausen, J., see Rasmussen, H.B. (184) 143
Clawson, S.A., see Greenlee, J.E. (184) 131
Codella, M., Rocca, M.A., Colombo, B., Martinelli-Boneschi, F., Comi, G. and Filippi, M.
Cerebral grey matter pathology and fatigue in patients with multiple sclerosis: a preliminary study (194) 71
Coglitore, S., see Vita, G. (186) 45
Colombo, B., see Codella, M. (194) 71
Colombo, R., see Mazzini, L. (191) 139
Combarros, O., see Berciano, J. (194) 75
Comi, G.P., see Sironi, M. (186) 51
Comi, G., see Inglese, M. (188) 33
Comi, G., see Codella, M. (194) 71
Comoletti, D., Muzio, V., Capobianco, A., Ravizza, T. and Mennini, T.
Nitric oxide produced by non-motoneuron cells enhances rat embryonic motoneuron sensitivity to excitotoxins: comparison in mixed neuron/glia or purified cultures (192) 61
Compston, D.A.S., see Hickman, S.J. (187) 35
Coshall, C., see Hajat, C. (190) 79
Cosi, V., see Bergamaschi, R. (189) 13
Cosi, V., see Franciotta, D. (190) 11
Cotelli, M., see Meola, G. (193) 89
Cottini, E., see Monastero, R. (184) 33
Crovella, S., see Masè, G. (191) 11
Cucchiara, B. and Kasner, S.E.
Use of statins in CNS disorders (187) 81
Cuccia, M., see Franciotta, D. (190) 11
Cui, L., see Wang, H. (194) 49
Cupini, L.M., see Diomedi, M. (185) 49

Dammacco, F., see Avolio, C. (186) 65
Das, R.R., see Behari, M. (190) 49
Davis, D.G., see Winters, J.L. (188) 13
Davis, L.E. and Kornfeld, M.
Experimental influenza B viral myositis (187) 61
Day, A.L., see He, Z. (193) 79
De Ambroggi, L., see Meola, G. (193) 89
De Ambrogio, R., see Mazzini, L. (191) 139
De Biasi, S., see Bendotti, C. (191) 25
DeFor, T.A., see Liu, X.-F. (187) 91
De Freitas, G.R., Miklossy, J., Christen-Zäch, S., Reichhart, M. and Bogousslavsky, J.
A CADASIL case with normal skin biopsy and without mutations in exons 3 and 4 of the *Notch3* gene (193) 43
De Gregorio, C., see Vita, G. (186) 45
Deguchi, K., Takeuchi, H., Sasaki, I., Tsukaguchi, M., Touge, T. and Nishioka, M.
Impaired novelty P3 potentials in multiple system atrophy—correlation with orthostatic hypotension (190) 61
Dehmeshki, J., Silver, N.C., Leary, S.M., Tofts, P.S., Thompson, A.J. and Miller, D.H.
Magnetisation transfer ratio histogram analysis of primary progressive and other multiple sclerosis subgroups (185) 11
Deitch, J.S., Alexander, G.M., Del Valle, L. and Heiman-Patterson, T.D.
GLT-1 glutamate transporter levels are unchanged in mice expressing G93A human mutant SOD1 (193) 117
Del Bene, M., see Albert, S.M. (191) 115
Del Bigio, M.R., Yan, H.-J. and Xue, M.
Intracerebral infusion of a second-generation ciliary neurotrophic factor reduces neuronal loss in rat striatum following experimental intracerebral hemorrhage (192) 53
Del Valle, L., see Deitch, J.S. (193) 117
Del Zotto, E., see Monastero, R. (184) 33
De Masi, R., see Zorzon, M. (187) 1
Dengler, R., see Krampfl, K. (191) 19
De Pablos, C., see Berciano, J. (194) 75
De Reuck, J., Santens, P., Strijckmans, K., Lemahieu, I. and Changes, E.T.F.A.-R.W.M.
Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes (193) 1
De Seze, J., Arndt, C., Stojkovic, T., Ayachi, M., Gauvrit, J.Y., Bughin, M., Saint Michel, T., Pruvo, J.P., Hache, J.C. and Vermersch, P.
Pupillary disturbances in multiple sclerosis: correlation with MRI findings (188) 37
DesRosiers, M., see Melun, J.-P. (186) 107
Dib, M., see Spreux-Varoquaux, O. (193) 73
Di Carlo, A., Perna, A.M., Pantoni, L., Basile, A.M., Bonacchi, M., Pracucci, G., Trefoloni, G., Bracco, L., Sangiovanni, V., Piccini, C., Palmarini, M.F., Carbonetto, F., Biondi, E., Sani, G. and Inzitari, D.
Clinically relevant cognitive impairment after cardiac surgery: a 6-month follow-up study (188) 85
Di Leo, R., see Vita, G. (186) 45
DiMauro, S., see Hadjigeorgiou, G.M. (194) 83
Diomedi, M., Cupini, L.M., Rizzato, B., Ferrante, F., Giacomini, P. and Silvestrini, M.
Influence of physiologic oscillation of estrogens on cerebral hemodynamics (185) 49
Dmochowski, J., see Bakshi, R. (185) 19
Dondi, E., see Franciotta, D. (190) 11
Dotti, M.T., see Mondelli, M. (190) 29
Dougan, C., see Lee, J.N. (191) 79
Dronsky, V., see Miller, R.G. (191) 127
Drory, V.E., Birnbaum, M., Korczyn, A.D. and Chapman, J.
Association of *APOE* ε4 allele with survival in amyotrophic lateral sclerosis (190) 17
Drory, V.E., Goltsman, E., Goldman Reznik, J., Mosek, A. and Korczyn, A.D.
The value of muscle exercise in patients with amyotrophic lateral sclerosis (191) 133
Dumas, M., see Bisser, S. (193) 127
Durelli, L., Oggero, A., Verdun, E., Isoardo, G.L., Barbero, P., Bergamasco, B., Brossa, P.C., Ghigo, E., Maccario, M., Faggiano, F. and The Betaferon® Safety Trial (BEST) Study Group
Thyroid function and anti-thyroid antibodies in MS patients screened for interferon treatment. A multicenter study (193) 17
Dyck, P.J., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Dyck, P.J.B., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Dziedzic, T., see Szczudlik, A. (189) 105

Eisen, A., see Stewart, H. (191) 67
Eisensehr, I., V Lindeiner, H., Jäger, M. and Noachtar, S.
REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography? (186) 7
Elovaara, I., see Luomala, M. (185) 123
Engvall, E., see O'Brien, D.P. (189) 37
Enomoto-Nakatani, S., see Hagiwara, H. (193) 59
Erbagci, I., see Yilmaz, M. (184) 139
Erdal, M.E., Herken, H., Yılmaz, M. and Bayazıt, Y.A.
Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine (188) 99
Erdal, M.E., see Yılmaz, M. (186) 27

Faggiano, F., see Durelli, L. (193) 17
Färkkilä, M., see Rantalaiho, T. (184) 169
Fawcett, J.R., see Liu, X.-F. (187) 91

Federico, A., see Mondelli, M. (190) 29
Fedetz, M., Matesanz, F., Pascual, M., Martín, J., Fernández, O., Guerrero, M. and Alcina, A.
The −174/−597 promoter polymorphisms in the interleukin-6 gene are not associated with susceptibility to multiple sclerosis (190) 69
Feldman, E.L., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Felisari, G., see Sironi, M. (186) 51
Felisari, G., see Montirosso, R. (194) 3
Fellner, C., see Hecht, M.J. (186) 37
Fellner, F., see Hecht, M.J. (186) 37
Fernández, O., see Fedetz, M. (190) 69
Ferrante, F., see Diomedi, M. (185) 49
Ferrara, F., see Caimi, G. (186) 23
Fiaschi, A., see Manganotti, P. (184) 27
Fields, H.L., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Filippi, M.
Multiple sclerosis: a white matter disease with associated gray matter damage (185) 3
Filippi, M., see Inglese, M. (188) 33
Filippi, M., see Codella, M. (194) 71
Filipponi, E., see Montirosso, R. (194) 3
Flabouriari, K., see Hadjigeorgiou, G.M. (194) 83
Forshew, D.A., see Bromberg, M.B. (184) 51
Franciotta, D., Cuccia, M., Dondi, E., Piccolo, G. and Cosi, V.
Polymorphic markers in MHC class II/III region: a study on Italian patients with myasthenia gravis (190) 11
Francis, D.A., see Rasmussen, H.B. (184) 143
Franzen, L., see Andersen, P.M. (191) 111
Frey II, W.H., see Liu, X.-F. (187) 91
Fries, T.J., see Bromberg, M.B. (184) 51
Fujihara, K., see Shimizu, H. (185) 39
Fujihara, K., see Tateyama, M. (194) 29
Fujii, K., see Toyoda, K. (193) 147
Fujimoto, H., Kaneko, K., Taguchi, T., Ofuji, A., Yonemura, H. and Kawai, S.
Differential recording of upper and lower cervical N13 responses and their contribution to scalp recorded responses in median nerve somatosensory evoked potentials (187) 17
Fujimoto, K.-i., see Namekawa, M. (187) 103
Fujimoto, S., see Shimazaki, R. (194) 55
Fujishima, K., see Noda, K. (188) 95
Fukae, J., see Noda, K. (188) 95
Fukuda, H., see Kikuchi, A. (193) 29
Fukui, T., Hasegawa, Y. and Takenaka, H.
Hyperthyroid dementia: clinicoradiological findings and response to treatment (184) 81
Fukuuchi, Y., see Suzuki, S. (189) 59
Funegård, U., see Andersen, P.M. (191) 111
Furusawa, K., see Tomiyama, M. (189) 65
Furuya, H., see Horiuchi, I. (193) 49
Furuya, H., see Oishi, A. (193) 151

Ganslandt, O., see Kamada, K. (186) 13
García-Lozano, J.-R., see Aguilera, I. (192) 81
García Gil, M.L., Morán, M.A. and Gómez-Ramos, P.
Ubiquitinated granular structures and initial neurofibrillary changes in the human brain (192) 27
Gauvrit, J.Y., see De Seze, J. (188) 37
Gelinas, D., see Jackson, C.E. (191) 75
Gelinas, D.F., see Miller, R.G. (191) 127
Gemignani, F. and Marbini, A.
Charcot–Marie–Tooth disease (CMT): distinctive phenotypic and genotypic features in CMT type 2 (184) 1
Gemma, A., see Masè, G. (191) 11
Ghigo, E., see Durelli, L. (193) 17
Giacomini, P., see Diomedi, M. (185) 49
Giacopuzzi, M., see Manganotti, P. (184) 27
Gill, J.S., see Russell, J.W. (192) 71
Giovanardi, F., see Guidetti, D. (184) 203
Giuliani, F., see Avolio, C. (186) 65
Giunti, D., see Mancardi, G. (184) 41
Gjerde, I.O., see Aarskog, N.K. (188) 21
Glosser, G., see Grossman, M. (184) 123
Goldman Reznik, J., see Drory, V.E. (191) 133
Goltsman, E., see Drory, V.E. (191) 133
Gómez-Ramos, P., see García Gil, M.L. (192) 27
Gootjes, L., see Bokde, A.L.W. (194) 35
Goto, J., see Hashida, H. (190) 87
Goto, K., see Nakagawa, M. (184) 15
Goto, K., see Noda, K. (188) 95
Gourie-Devi, M., see Shahani, N. (185) 109
Grad, A., see Meglič, B. (185) 135
Graff-Radford, N.R., see Caselli, R.J. (189) 93
Grant, I.A., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Grau, A.J., Buggle, F., Lichy, C., Brandt, T., Becher, H. and Rudi, J.
Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin (186) 1
Grau, A.J., Reis, A., Buggle, F., Al-Khalaf, A., Werle, E., Valois, N., Bertram, M., Becher, H. and Grond-Ginsbach, C.
Monocyte function and plasma levels of interleukin-8 in acute ischemic stroke (192) 41
Graus, F., see Meglič, B. (185) 135
Green, C., see Kiebert, G.M. (191) 87
Greenlee, J.E., Boyden, J.W., Pingree, M., Brashear, H.R., Clawson, S.A. and Keeney, P.M.
Antibody types and IgG subclasses in paraneoplastic neurological syndromes (184) 131
Griffin, J.W., see Ad Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Groeneveld, G.J., Van Kan, H.J.M., Sastre Toraño, J., Veldink, J.H., Guchelaar, H.-J., Wokke, J.H.J. and Van den Berg, L.H.
Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS (191) 121
Grönberg, H., see Andersen, P.M. (191) 111
Grond-Ginsbach, C., see Grau, A.J. (192) 41
Grossman, M., Glosser, G., Kalmanson, J., Morris, J., Stern, M.B. and Hurtig, H.I.
Dopamine supports sentence comprehension in Parkinson's Disease (184) 123
Grothe, C., see Pohl, C. (190) 21
Guchelaar, H.-J., see Groeneveld, G.J. (191) 121
Guerrero, M., see Fedetz, M. (190) 69
Guidetti, D., Pisanello, A., Giovanardi, F., Morandi, C., Zuccoli, G. and Troiso, A.
Spontaneous carotid dissection presenting lower cranial nerve palsies (184) 203
Guo, L.T., see O'Brien, D.P. (189) 37

Hache, J.C., see De Seze, J. (188) 37
Hadjigeorgiou, G.M., Papadimitriou, A., Musumeci, O., Paterakis, K., Flabouriari, K., Shanske, S. and DiMauro, S.
A new stop codon mutation (Y52X) in the myophosphorylase gene in a Greek patient with McArdle's disease (194) 83
Hagiwara, H., Enomoto-Nakatani, S., Sakai, K., Ugawa, Y., Kusunoki, S. and Kanazawa, I.
Stiff-person syndrome associated with invasive thymoma: a case report (193) 59
Hajat, C., Coshall, C., Rudd, A.G., Patel, M., Bhalla, A., Howard, R. and Wolfe, C.D.A.
The inter- and intraobserver reliabilities of a new classification system for ischaemic stroke: the South London Stroke Register (190) 79

Hall, G.R., see Caselli, R.J. (189) 93
Hämäläinen, P., see Laatu, S. (185) 77
Hampel, H., Teipel, S.J., Bayer, W., Alexander, G.E., Schwarz, R., Schapiro, M.B., Rapoport, S.I. and Möller, H.-J.
Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease (194) 15
Hampel, H., see Bokde, A.L.W. (194) 35
Hanyu, H., Asano, T., Sakurai, H., Takasaki, M., Shindo, H. and Abe, K.
Magnetization transfer measurements of the hippocampus in the early diagnosis of Alzheimer's disease (188) 79
Haraguchi, T., see Yokota, O. (194) 41
Hardy, J., see Caselli, R.J. (189) 93
Harness, J., Pender, M.P. and McCombe, P.A.
Cyclosporin A treatment modulates cytokine mRNA expression by inflammatory cells extracted from the spinal cord of rats with experimental autoimmune encephalomyelitis induced by inoculation with myelin basic protein (187) 7
Hart, B., see Mancardi, G. (184) 41
Hasegawa, Y., see Fukui, T. (184) 81
Hashida, H., Goto, J., Suzuki, T., Jeong, S.-Y., Masuda, N., Ooie, T., Tachiiri, Y., Tsuchiya, H. and Kanazawa, I.
Single cell analysis of CAG repeat in brains of dentatorubral-pallidoluysian atrophy (DRPLA) (190) 87
Hashiguchi, T., see Matsuyama, W. (186) 75
Hashimoto, K., see Katayama, T. (193) 37
Hattori, N., Misu, K., Koike, H., Ichimura, M., Nagamatsu, M., Hirayama, M. and Sobue, G.
Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy (184) 57
Hattori, N., see Yoshihara, T. (184) 149
Hattori, T., see Sakakibara, R. (187) 55
Hayashi, S., Sakurai, A., Amari, M. and Okamoto, K.
Pathological study of the diffuse myelin pallor in the anterolateral columns of the spinal cord in amyotrophic lateral sclerosis (188) 3
Hayashi, T., see Murakami, T. (189) 45
Hayashi, T., see Manabe, Y. (193) 13
He, Y.-J., see He, Z. (193) 79
He, Z., He, Y.-J., Day, A.L. and Simpkins, J.W.
Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and-independent mechanisms (193) 79
Heberlin, L., see Jackson, C.E. (191) 75
Hecht, M.J., Fellner, F., Fellner, C., Hilz, M.J., Heuss, D. and Neundörfer, B.
MRI-FLAIR images of the head show corticospinal tract alterations in ALS patients more frequently than T2-, T1- and proton-density-weighted images (186) 37
Heiman-Patterson, T.D., see Deitch, J.S. (193) 117
Hentz, J.G., see Caselli, R.J. (189) 93
Herken, H., see Yılmaz, M. (186) 27
Herken, H., see Erdal, M.E. (188) 99
Heuss, D., see Hecht, M.J. (186) 37
Hickman, S.J., Brierley, C.M.H., Silver, N.C., Moseley, I.F., Scolding, N.J., Compston, D.A.S. and Miller, D.H.
Infratentorial hypointense lesion volume on T1-weighted magnetic resonance imaging correlates with disability in patients with chronic cerebellar ataxia due to multiple sclerosis (187) 35
Higo, R., see Yamasoba, T. (187) 69
Higuchi, I., see Nakagawa, M. (184) 15
Hilz, M.J., see Hecht, M.J. (186) 37
Hino, H., see Shiozaki, K. (193) 23
Hintzen, R.Q., see Kalkers, N.F. (184) 155
Hintzen, R.Q., see Kalkers, N.F. (187) 111
Hirano, T., see Toyoda, K. (193) 147
Hirata, K., see Susuki, K. (185) 5
Hirayama, M., see Hattori, N. (184) 57
Hogan, E.L., see Lo, H.-S. (194) 11
Honjo, K., see Naka, H. (193) 111
Hopf, H.C., see Urban, P.P. (186) 59
Horiuchi, I., Ochi, H., Murai, H., Osoegawa, M., Minohara, M., Furuya, H. and Kira, J.-i.
Th2 shift in mononeuritis multiplex and increase of Th2 cells in chronic inflammatory demyelinating polyneuropathy: an intracellular cytokine analysis (193) 49
Howard, R., see Hajat, C. (190) 79
Hu, C.-J., see Tsai, C.-H. (190) 35
Hu, J., see Ono, S. (187) 27
Huang, N., see Nitrini, R. (184) 163
Hung, Y.-C., see Lee, E.-J. (190) 3
Hurme, M., see Luomala, M. (185) 123
Hurtig, H.I., see Grossman, M. (184) 123

Iannaccone, S., see Miller, R.G. (191) 127
Ibayashi, S., see Toyoda, K. (193) 147
Ichikawa, M., see Inaba, Y. (185) 89
Ichimura, M., see Hattori, N. (184) 57
Ikeda, K., see Yokota, O. (194) 41
Ikeda, S.-i., see Matsuda, M. (184) 189
Imai, T., see Ono, S. (187) 27
Imai, Y., see Manabe, Y. (193) 13
Imon, Y., see Naka, H. (193) 111
Imperiale, D., see Montalenti, E. (184) 65
Inaba, Y., Ichikawa, M., Inoue, A., Itoh, M., Kyogashima, M., Sekiguchi, Y., Nakamura, S., Komiyama, A. and Koh, C.-S.
Plasma thrombin–antithrombin III complex is associated with the severity of experimental autoimmune encephalomyelitis (185) 89
Inglese, M., Rovaris, M., Bianchi, S., Comi, G. and Filippi, M.
Magnetization transfer and diffusion tensor MR imaging of the optic radiations and calcarine cortex from patients with Leber's hereditary optic neuropathy (188) 33
Inoue, A., see Inaba, Y. (185) 89
Inoue, M., see Yoshida, T. (184) 77
Inzitari, D., see Di Carlo, A. (188) 85
Iseki, E., Kato, M., Marui, W., Uéda, K. and Kosaka, K.
A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies (185) 129
Iseki, E., see Togo, T. (184) 71
Iseki, E., see Shiozaki, K. (193) 23
Ishida, K., Takeuchi, H., Takahashi, R., Yoshimura, K., Yamada, M. and Mizusawa, H.
A possible novel isoform of peripheral myelin P0 protein: a target antigen recognized by an autoantibody in a patient with malignant lymphoma and peripheral neuropathy (188) 43
Ishigame, H., see Matsuda, M. (184) 189
Ishihara, H., see Yoshihara, T. (184) 149
Ishii, N., see Tateyama, M. (194) 29
Ishikawa, M., Sekizuka, E., Oshio, C., Sato, S., Yamaguchi, N., Terao, S., Tsukada, K., Minamitani, H. and Kawase, T.
Platelet adhesion and arteriolar dilation in the photothrombosis: observation with the rat closed cranial and spinal windows (194) 59
Ishizu, H., see Yokota, O. (194) 41
Iskra, T., see Szczudlik, A. (189) 105
Isoardo, G.L., see Durelli, L. (193) 17
Italian ALS Study Group, see Chiò, A. (191) 145
Itoh, M., see Inaba, Y. (185) 89
Itoyama, Y., see Shimizu, H. (185) 39
Itoyama, Y., see Kikuchi, A. (193) 29
Itoyama, Y., see Tateyama, M. (194) 29
Iudice, A., see Siciliano, G. (191) 61
Iwatsuki, K., see Manabe, Y. (193) 13

Jackson, C.E., Rosenfeld, J., Moore, D.H., Bryan, W.W., Barohn, R.J., Wrench, M., Myers, D., Heberlin, L., King, R., Smith, J., Gelinas, D. and Miller, R.G.
A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients (191) 75
Jackson, P.F., see Zhang, W. (194) 21
Jacobs, L., see Bakshi, R. (185) 19
Jäger, M., see Eisensehr, I. (186) 7
Jain, S., see Murgod, U.A. (190) 73
Jauberteau, M.O., see Bisser, S. (193) 127
Jeong, S.-Y., see Hashida, H. (190) 87
Jhoo, J.H., Kim, K.W., Lee, D.Y., Lee, K.U., Lee, J.H., Kim, S.Y., Youn, J.Y., Youn, J.C. and Woo, J.I.
Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer's disease in Koreans (184) 21
Jia, L., see Yu, K. (189) 23
Johnson, G.C., see O'Brien, D.P. (189) 37
Jong, Y.-J., see Tsai, C.-H. (190) 35
Josephson, S.A., Schmidt, R.E., Millsap, P., McManus, D.Q. and Morris, J.C.
Autosomal dominant Kufs' disease: a cause of early onset dementia (188) 51
Jurjevic, A., see Masè, G. (191) 11

Kafri, M., see Wang, N. (184) 183
Kaji, R., see Mizutani, K. (188) 9
Kalita, J., see Misra, U.K. (190) 57
Kalkers, N.F., Hintzen, R.Q., Van Waesberghe, J.H.T.M., Lazeron, R.H.C., Van Schijndel, R.A., Adèr, H.J., Polman, C.H. and Barkhof, F.
Erratum to "Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy" [J. Neurol. Sci. 184 (2001) 155–162] (187) 111
Kalkers, N.F., Hintzen, R.Q., Van Waesberghe, J.H.T.M., Lazeron, R.H.C., Van Schijndel, R.A., Adèr, H.J., Polman, C.H. and Barkhof, F.
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy (184) 155
Kalmanson, J., see Grossman, M. (184) 123
Kaltenhäuser, M., see Kamada, K. (186) 13
Kamada, K., Möller, M., Saguer, M., Ganslandt, O., Kaltenhäuser, M., Kober, H. and Vieth, J.
A combined study of tumor-related brain lesions using MEG and proton MR spectroscopic imaging (186) 13
Kamakura, K., see Yoshida, T. (184) 77
Kametani, F., Tanaka, K., Usami, M., Maruyama, K. and Mori, H.
Human wild presenilin-1 mimics the effect of the mutant presenilin-1 on the processing of Alzheimer's amyloid precursor protein in PC12D cells (188) 27
Kanazawa, I., see Hashida, H. (190) 87
Kanazawa, I., see Hagiwara, H. (193) 59
Kanda, F., see Yoshihara, T. (184) 149
Kaneko, K., see Fujimoto, H. (187) 17
Kang, D.-W., see Chu, K. (185) 27
Kanzato, N., see Nakagawa, M. (184) 15
Karitzky, J. and Ludolph, A.C.
Imaging and neurochemical markers for diagnosis and disease progression in ALS (191) 35
Kasner, S.E., see Cucchiara, B. (187) 81
Katayama, T., Aizawa, H., Kuroda, K., Suzuki, Y., Kikuchi, K., Kimura, T., Hashimoto, K. and Yahara, O.
Cortical silent period in the tongue induced by transcranial magnetic stimulation (193) 37
Kato, M., see Iseki, E. (185) 129
Kaufmann, K. and Thiel, G.
Epidermal growth factor and platelet-derived growth factor induce expression of *Egr-1*, a zinc finger transcription factor, in human malignant glioma cells (189) 83
Kawabata, K., see Okuda, B. (187) 99
Kawabata, M., see Matsuyama, W. (186) 75
Kawai, K., see Yokota, O. (194) 41
Kawai, S., see Fujimoto, H. (187) 17
Kawakami, Y., see Suzuki, S. (189) 59
Kawase, T., see Ishikawa, M. (194) 59
Kawashima, R., see Kikuchi, A. (193) 29
Kawata, A., see Tanaka, M. (188) 61
Keeney, P.M., see Greenlee, J.E. (184) 131
Keilmann, A., see Urban, P.P. (186) 59
Kelly, M.A., see Rasmussen, H.B. (184) 143
Kiebert, G.M., Green, C., Murphy, C., Mitchell, J.D., O'Brien, M., Burrell, A. and Leigh, P.N.
Patients' health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis (191) 87
Kikuchi, A., Takeda, A., Kimpara, T., Nakagawa, M., Kawashima, R., Sugiura, M., Kinomura, S., Fukuda, H., Chida, K., Okita, N., Takase, S. and Itoyama, Y.
Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease (193) 29
Kikuchi, K., see Katayama, T. (193) 37
Kikuchi, S., see Yamasoba, T. (187) 69
Kim, D.-E., see Chu, K. (185) 27
Kim, K.W., see Jhoo, J.H. (184) 21
Kim, S.Y., see Jhoo, J.H. (184) 21
Kimpara, T., see Kikuchi, A. (193) 29
Kimura, T., see Tomiyama, M. (189) 65
Kimura, T., see Katayama, T. (193) 37
King, R., see Jackson, C.E. (191) 75
Kinomura, S., see Kikuchi, A. (193) 29
Kinoshita, M., see Nemoto, H. (193) 7
Kira, J.-i., see Tanaka, M. (188) 61
Kira, J.-i., see Horiuchi, I. (193) 49
Kira, J.-i., see Oishi, A. (193) 151
Kiritoshi, S., see Toyoda, K. (193) 147
Kissel, J., see Miller, R.G. (191) 127
Kitamura, T., see Naka, H. (193) 111
Klein, C., see Kushnir, M. (186) 101
Klein, C.J., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Klier, H., see Wasner, M. (191) 151
Klockgether, T., see Schmidt, S. (187) 49
Klockgether, T., see Pohl, C. (190) 21
Kobayashi, Y., see Yoshida, T. (184) 77
Kober, H., see Kamada, K. (186) 13
Koh, C.-S., see Inaba, Y. (185) 89
Koike, H., see Hattori, N. (184) 57
Koivula, T., see Luomala, M. (185) 123
Kojima, S., see Tanaka, M. (188) 61
Koleva, M., see Kostova, V. (192) 17
Komiyama, A., see Inaba, Y. (185) 89
Kondo, T., see Miwa, H. (193) 97
Kono, S., see Miyajima, H. (184) 197
Korczyn, A.D., see Wang, N. (184) 183
Korczyn, A.D., see Drory, V.E. (190) 17
Korczyn, A.D., see Drory, V.E. (191) 133
Kornberg, A.J., see Lopate, G. (188) 67
Kornfeld, M., see Davis, L.E. (187) 61
Kosaka, K., see Togo, T. (184) 71
Kosaka, K., see Iseki, E. (185) 129
Kosaka, K., see Shiozaki, K. (193) 23
Koskiniemi, M., see Rantalaiho, T. (184) 169

Kostova, V. and Koleva, M.
Back disorders (low back pain, cervicobrachial and lumbosacral radicular syndromes) and some related risk factors (192) 17
Krampfl, K., Schlesinger, F., Wolfes, H., Dengler, R. and Bufler, J.
Functional diversity of recombinant human AMPA type glutamate receptors: possible implications for selective vulnerability ofmotor neurons (191) 19
Krismann, M., see Sindern, E. (186) 81
Kubota, T., see Oishi, A. (193) 151
Kumai, Y., see Toyoda, K. (193) 147
Kumamoto, T., see Shimazaki, R. (194) 55
Kurahashi, K., see Tomiyama, M. (189) 65
Kuroda, K., see Katayama, T. (193) 37
Kuroda, S., see Yokota, O. (194) 41
Kuroda, Y., see Satoh, J.-i. (189) 113
Kurokawa, T., see Tanaka, M. (188) 61
Kushnir, M., Klein, C. and Rabey, J.M.
H reflex behavior in Parkinson's disease patients and patients with extrapyramidal and pyramidal signs combined (186) 101
Kusumi, M., see Mori, M. (185) 43
Kusunoki, S., see Mizutani, K. (188) 9
Kusunoki, S., see Hagiwara, H. (193) 59
Kuwana, M., see Suzuki, S. (189) 59
Kyogashima, M., see Inaba, Y. (185) 89

Laatu, S., Revonsuo, A., Hämäläinen, P., Ojanen, V. and Ruutiainen, J.
Visual object recognition in multiple sclerosis (185) 77
Lacomblez, L., see Le Forestier, N. (185) 95
Lacomblez, L., see Spreux-Varoquaux, O. (193) 73
Laippala, P., see Luomala, M. (185) 123
Lanotte, M., see Perozzo, P. (192) 9
Lanzillo, B., see Perretti, A. (192) 35
Lazeron, R.H.C., see Kalkers, N.F. (184) 155
Lazeron, R.H.C., see Kalkers, N.F. (187) 111
Leary, S.M., see Dehmeshki, J. (185) 11
LeBlanc, A., see Nitrini, R. (184) 163
Lee, D.Y., see Jhoo, J.H. (184) 21
Lee, E.-J. and Hung, Y.-C.
Marked anemic hypoxia deteriorates cerebral hemodynamics and brain metabolism during massive intracerebral hemorrhage (190) 3
Lee, J.H., see Jhoo, J.H. (184) 21
Lee, J.N., Rigby, S.A., Burchardt, F., Thornton, E.W., Dougan, C. and Young, C.A.
Quality of life issues in motor neurone disease: the development and validation of a coping strategies questionnaire, the MND Coping Scale (191) 79
Lee, K.U., see Jhoo, J.H. (184) 21
Le Forestier, N., Maisonobe, T., Spelle, L., Lesort, A., Salachas, F., Lacomblez, L., Samson, Y., Bouche, P. and Meininger, V.
Primary lateral sclerosis: further clarification (185) 95
Le Forestier, N., see Spreux-Varoquaux, O. (193) 73
Lehtimäki, T., see Luomala, M. (185) 123
Leigh, P.N., see Kiebert, G.M. (191) 87
Leinsinger, G., see Bokde, A.L.W. (194) 35
Lejon, V., see Bisser, S. (193) 127
Lemahieu, I., see De Reuck, J. (193) 1
Leshner, R., see Miller, R.G. (191) 127
Lesort, A., see Le Forestier, N. (185) 95
Levine, D.N. and Rapalino, O.
The pathophysiology of lumbar puncture headache (192) 1
Li, J., see Yu, K. (189) 23
Li, Y., Chen, J. and Chopp, M.
Cell proliferation and differentiation from ependymal, subependymal and choroid plexus cells in response to stroke in rats (193) 137
Li, Y., see Chen, J. (189) 49
Lichy, C., see Grau, A.J. (186) 1
Lin, X. and Blumhardt, L.D.
Inflammation and atrophy in multiple sclerosis: MRI associations with disease course (189) 99
Lindblom, U., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Lindsberg, P.J., see Sairanen, T.R. (186) 87
Link, H., see Press, R. (190) 41
Litchy, W.J., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Liu, L.A., see O'Brien, D.P. (189) 37
Liu, X.-F., Fawcett, J.R., Thorne, R.G., DeFor, T.A. and Frey II, W.H.
Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage (187) 91
Livramento, J.A., see Nitrini, R. (184) 163
Livrea, P., see Avolio, C. (186) 65
Lo, H.-S., Hogan, E.L. and Soong, B.-W.
5′-Flanking region polymorphism of the neuronal nitric oxide synthase gene with Parkinson's disease in Taiwan (194) 11
Lo, Y.L., see Tan, E.K. (190) 95
Lolli, F., see Press, R. (190) 41
Lopate, G., Kornberg, A.J., Yue, J., Choksi, R. and Pestronk, A.
Anti-myelin associated glycoprotein antibodies: variability in patterns of IgM binding to peripheral nerve (188) 67
Lopiano, L., see Perozzo, P. (192) 9
Lo Presti, R., see Caimi, G. (186) 23
Love, S., see Perunovic, B. (185) 55
Low, P.A., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Lu, M., see Chen, J. (189) 49
Ludolph, A.C., see Karitzky, J. (191) 35
Luomala, M., Lehtimäki, T., Elovaara, I., Wang, X.-Y., Ukkonen, M., Mattila, K., Laippala, P., Koivula, T. and Hurme, M.
A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis (185) 123

Maccario, M., see Durelli, L. (193) 17
Maeda, T., see Tomiyama, M. (189) 65
Maisonobe, T., see Le Forestier, N. (185) 95
Malek, M., see Tavakoli, M. (191) 95
Malin, J.P., see Sindern, E. (186) 81
Manabe, Y., Murakami, T., Iwatsuki, K., Narai, H., Warita, H., Hayashi, T., Shoji, M., Imai, Y. and Abe, K.
Nocturnal blood pressure dip in CADASIL (193) 13
Manabe, Y., see Murakami, T. (189) 45
Manca, M.L., see Siciliano, G. (191) 61
Mancardi, G., Hart, B., Roccatagliata, L., Brok, H., Giunti, D., Bontrop, R., Massacesi, L., Capello, E. and Uccelli, A.
Demyelination and axonal damage in a non-human primate model of multiple sclerosis (184) 41
Manganotti, P., Bortolomasi, M., Zanette, G., Pawelzik, T., Giacopuzzi, M. and Fiaschi, A.
Intravenous clomipramine decreases excitability of human motor cortex. A study with paired magnetic stimulation (184) 27
Marbini, A., see Gemignani, F. (184) 1
Marie, S.K., see Nitrini, R. (184) 163
Marinou, K., see Meola, G. (193) 89
Marouan, A., see Spreux-Varoquaux, O. (193) 73
Martín, J., see Fedetz, M. (190) 69
Martinelli-Boneschi, F., see Codella, M. (194) 71
Marui, W., see Togo, T. (184) 71
Marui, W., see Iseki, E. (185) 129

Maruyama, I., see Matsuyama, W. (186) 75
Maruyama, K., see Kametani, F. (188) 27
Masè, G., Ros, S., Gemma, A., Bonfigli, L., Carraro, N., Cazzato, G., Rolfo, M., Zanconati, F., Sepcic, J., Jurjevic, A., Pirulli, D., Boniotto, M., Zezlina, S., Crovella, S. and Amoroso, A.
ALS with variable phenotypes in a six-generation family caused by leu144phe mutation in the *SOD1* gene (191) 11
Masjuan, J., see Cid, C. (193) 103
Massacesi, L., see Mancardi, G. (184) 41
Masuda, N., see Hashida, H. (190) 87
Matá, S., see Press, R. (190) 41
Mateo, I., see Berciano, J. (194) 75
Matesanz, F., see Fedetz, M. (190) 69
Matsuda, M., Tabata, K.-i., Miki, J., Ishigame, H., Asano, M. and Ikeda, S.-i.
Multiple sclerosis with secondary syringomyelia An autopsy report (184) 189
Matsumura, T., see Nakagawa, M. (184) 15
Matsunaga, M., see Tomiyama, M. (189) 65
Matsuura, E., see Matsuyama, W. (186) 75
Matsuyama, W., Hashiguchi, T., Umehara, F., Matsuura, E., Kawabata, M., Arimura, K., Maruyama, I. and Osame, M.
Expression of vascular endothelial growth factor in tuberculous meningitis (186) 75
Matsuyama, W., see Nakagawa, M. (185) 31
Matsuzaki, T., see Nakagawa, M. (184) 15
Mattila, K., see Luomala, M. (185) 123
Mayer, R.F.
The motor unit and electromyography—the legacy of Derek Denny-Brown (189) 7
Mazzini, L., Balzarini, C., Colombo, R., Mora, G., Pastore, I., De Ambrogio, R. and Caligari, M.
Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results (191) 139
McCombe, P.A., see Harness, J. (187) 7
McManus, D.Q., see Josephson, S.A. (188) 51
Medina, M.T. and Munsat, T.
Continuing medical education in developing countries (190) 1
Meglič, B., Graus, F. and Grad, A.
Anti-Yo-associated paraneoplastic cerebellar degeneration in a man with gastric adenocarcinoma (185) 135
Meininger, V., see Le Forestier, N. (185) 95
Meininger, V., see Spreux-Varoquaux, O. (193) 73
Melanson, M., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Melun, J.-P., Morin, L.M., Muise, J.G. and DesRosiers, M.
Color vision deficiencies in Gilles de la Tourette syndrome (186) 107
Mendell, J., see Miller, R.G. (191) 127
Mendell, J.R., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Mendonça, R.A., see Nitrini, R. (184) 163
Mendoza, M., see Miller, R.G. (191) 127
Mennini, T., see Comoletti, D. (192) 61
Meola, G., Sansone, V., Marinou, K., Cotelli, M., Moxley III, R.T., Thornton, C.A. and De Ambroggi, L.
Proximal myotonic myopathy: a syndrome with a favourable prognosis? (193) 89
Merren, M.D., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Messina, C., see Vita, G. (186) 45
Mezaki, T., see Mizutani, K. (188) 9
Mezei, M., see Stewart, H. (191) 67
Miki, J., see Matsuda, M. (184) 189
Miklossy, J., see De Freitas, G.R. (193) 43
Miller, D.H., see Dehmeshki, J. (185) 11
Miller, D.H., see Hickman, S.J. (187) 35
Miller, R.G., Moore, D.H., Dronsky, V., Bradley, W., Barohn, R., Bryan, W., Prior, T.W., Gelinas, D.F., Iannaccone, S., Kissel, J., Leshner, R., Mendell, J., Mendoza, M., Russman, B., Samaha, F., Smith, S. and SMA Study Group
A placebo-controlled trial of gabapentin in spinal muscular atrophy (191) 127
Miller, R.G., see Jackson, C.E. (191) 75
Millsap, P., see Josephson, S.A. (188) 51
Mimori, Y., see Naka, H. (193) 111
Minamitani, H., see Ishikawa, M. (194) 59
Minohara, M., see Horiuchi, I. (193) 49
Misra, U.K. and Kalita, J.
Seizures in Japanese encephalitis (190) 57
Misu, K., see Hattori, N. (184) 57
Misu, K.-i., see Yoshihara, T. (184) 149
Mitchell, J.D., see Kiebert, G.M. (191) 87
Mitsumoto, H., see Albert, S.M. (191) 115
Miwa, H., Mizuno, Y. and Kondo, T.
Familial hemifacial spasm: report of cases and review of literature (193) 97
Miyajima, H., Ouchi, Y., Sakamoto, M., Takahashi, Y., Kono, S. and Suzuki, H.
Increased anaerobic glycolysis in mitochondrial trifunctional protein-deficient brain (184) 197
Miyashita, F., see Nakagawa, M. (185) 31
Mizuno, S., see Murakami, T. (189) 45
Mizuno, Y., see Noda, K. (188) 95
Mizuno, Y., see Miwa, H. (193) 97
Mizusawa, H., see Ishida, K. (188) 43
Mizutani, K., Oka, N., Kusunoki, S., Kaji, R., Mezaki, T., Akiguchi, I. and Shibasaki, H.
Sensorimotor demyelinating neuropathy with IgM antibody against gangliosides GD1a, GT1b and GM3 (188) 9
Moeller, H.-J., see Bokde, A.L.W. (194) 35
Moggio, M., see Sironi, M. (186) 51
Moggio, M., see Bendotti, C. (191) 25
Möller, H.-J., see Hampel, H. (194) 15
Möller, M., see Kamada, K. (186) 13
Monastero, R., Bettini, P., Del Zotto, E., Cottini, E., Tincani, A., Balestrieri, G., Cattaneo, R., Camarda, R., Vignolo, L.A. and Padovani, A.
Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations (184) 33
Mondelli, M., Sicurelli, F., Scarpini, C., Dotti, M.T. and Federico, A.
Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study (190) 29
Montalenti, E., Imperiale, D., Rovera, A., Bergamasco, B. and Benna, P.
Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients (184) 65
Montana, M., see Caimi, G. (186) 23
Monti Bragadin, L., see Zorzon, M. (187) 1
Montirosso, R., Brambilla, D., Felisari, G., Sclaunich, F., Filipponi, E., Pozzoli, U. and Bresolin, N.
Electrophysiological analysis of cognitive slowing in subjects with mitochondrial encephalomyopathy (194) 3
Moore, D.H., see Jackson, C.E. (191) 75
Moore, D.H., see Miller, R.G. (191) 127
Mora, G., see Mazzini, L. (191) 139
Morán, M.A., see García Gil, M.L. (192) 27
Morandi, C., see Guidetti, D. (184) 203
Moretti, R., see Zorzon, M. (187) 1
Mori, H., see Kametani, F. (188) 27
Mori, M., Adachi, Y., Kusumi, M. and Nakashima, K.
Spinocerebellar ataxia type 6: founder effect in Western Japan (185) 43
Mori, M., see Shimazaki, R. (194) 55

Mori, T., see Shimazaki, R. (194) 55
Morin, L.M., see Melun, J.-P. (186) 107
Morris, J., see Grossman, M. (184) 123
Morris, J.C., see Josephson, S.A. (188) 51
Mosek, A., see Drory, V.E. (191) 133
Moseley, I.F., see Hickman, S.J. (187) 35
Mowzoon, N., Sussman, A. and Bradley, W.G.
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis (185) 119
Moxley III, R.T., see Meola, G. (193) 89
Muise, J.G., see Melun, J.-P. (186) 107
Muñoz, A., see Aguilera, I. (192) 81
Munsat, T., see Medina, M.T. (190) 1
Murai, H., see Horiuchi, I. (193) 49
Murakami, T., Warita, H., Hayashi, T., Sato, K., Manabe, Y., Mizuno, S., Yamane, K. and Abe, K.
A novel SOD1 gene mutation in familial ALS with low penetrance in females (189) 45
Murakami, T., see Manabe, Y. (193) 13
Murakawa, Y., see Zhang, W. (194) 21
Murali, T., see Nair, K.P.S. (187) 77
Muramatsu, S.-i., see Namekawa, M. (187) 103
Murgod, U.A., Saleem, Q., Anand, A., Brahmachari, S.K., Jain, S. and Muthane, U.B.
A clinical study of patients with genetically confirmed Huntington's disease from India (190) 73
Murphy, C., see Kiebert, G.M. (191) 87
Murphy, J.R., see Sanjak, M. (191) 55
Murphy, P.L., see Albert, S.M. (191) 115
Murri, L., see Siciliano, G. (191) 61
Musallam, S., see Wong, A.M.F. (189) 71
Musso, M., see Caimi, G. (186) 23
Musumeci, O., see Hadjigeorgiou, G.M. (194) 83
Muthane, U.B., see Murgod, U.A. (190) 73
Muzio, V., see Comoletti, D. (192) 61
Myers, D., see Jackson, C.E. (191) 75

Nagaki, H., see Shimazaki, H. (185) 101
Nagamatsu, M., see Hattori, N. (184) 57
Nair, K.P.S., Taly, A.B., Rao, S. and Murali, T.
Afferent pathways of sympathetic skin response in spinal cord: a clinical and electrophysiological study (187) 77
Naka, H., Imon, Y., Ohshita, T., Honjo, K., Kitamura, T., Mimori, Y. and Nakamura, S.
Magnetization transfer measurements of cerebral white matter in patients with myotonic dystrophy (193) 111
Nakagawa, H., see Ono, S. (187) 27
Nakagawa, M., Matsuzaki, T., Suehara, M., Kanzato, N., Takashima, H., Higuchi, I., Matsumura, T., Goto, K., Arahata, K. and Osame, M.
Phenotypic variation in a large Japanese family with Miyoshi myopathy with nonsense mutation in exon 19 of *dysferlin* gene (184) 15
Nakagawa, M., Takashima, H., Umehara, F., Arimura, K., Miyashita, F., Takenouchi, N., Matsuyama, W. and Osame, M.
Clinical phenotype in X-linked Charcot-Marie-Tooth disease with an entire deletion of the *connexin 32* coding sequence (185) 31
Nakagawa, M., see Kikuchi, A. (193) 29
Nakamura, S., see Inaba, Y. (185) 89
Nakamura, S., see Naka, H. (193) 111
Nakano, I., see Namekawa, M. (185) 63
Nakano, I., see Shimazaki, H. (185) 101
Nakano, I., see Namekawa, M. (187) 103
Nakashima, K., see Mori, M. (185) 43
Nakashima, K., see Nomura, T. (187) 41
Nalini, A., see Shahani, N. (185) 109
Namekawa, M., Takiyama, Y., Ando, Y., Sakoe, K., Muramatsu, S.-i., Fujimoto, K.-i., Nishizawa, M. and Nakano, I.
Choreiform movements in spinocerebellar ataxia type 1 (187) 103
Namekawa, M., Takiyama, Y., Sakoe, K., Shimazaki, H., Amaike, M., Niijima, K., Nakano, I. and Nishizawa, M.
A large Japanese SPG4 family with a novel insertion mutation of the *SPG4* gene: a clinical and genetic study (185) 63
Namekawa, M., see Shimazaki, H. (185) 101
Narai, H., see Manabe, Y. (193) 13
Narayanaswami, P. and Bertorini, T.E.
Progressive amyotrophy as a late complication of myelopathy (184) 11
Nasuelli, D., see Zorzon, M. (187) 1
Nemoto, H., Nemoto, K., Sugimoto, H. and Kinoshita, M.
FK506 suppressed the inflammatory change of EAM in SJL/J mice (193) 7
Nemoto, K., see Nemoto, H. (193) 7
Neudert, C., Wasner, M. and Borasio, G.D.
Patients' assessment of quality of life instruments: a randomised study of SIP, SF-36 and SEIQoL-DW in patients with amyotrophic lateral sclerosis (191) 103
Neundörfer, B., see Hecht, M.J. (186) 37
Neville, H.E., see Sanjak, M. (191) 55
Niijima, K., see Namekawa, M. (185) 63
Nishioka, M., see Deguchi, K. (190) 61
Nishizawa, M., see Namekawa, M. (185) 63
Nishizawa, M., see Shimazaki, H. (185) 101
Nishizawa, M., see Namekawa, M. (187) 103
Nitrini, R., Mendonça, R.A., Huang, N., LeBlanc, A., Livramento, J.A. and Marie, S.K.
Diffusion-weighted MRI in two cases of familial Creutzfeldt–Jakob disease (184) 163
Noachtar, S., see Eisensehr, I. (186) 7
Noda, K., Okuma, Y., Fukae, J., Fujishima, K., Goto, K., Sadamasa, H., Yoshiike, T. and Mizuno, Y.
Sweet's syndrome associated with encephalitis (188) 95
Nomura, S., see Yoshida, T. (184) 77
Nomura, T., Takeshima, T. and Nakashima, K.
Reduced pre-movement facilitation of motor evoked potentials in spinocerebellar degeneration (187) 41
Nose, S., see Yokota, O. (194) 41

O'Brien, D.P., Johnson, G.C., Liu, L.A., Guo, L.T., Engvall, E., Powell, H.C. and Shelton, G.D.
Laminin α2 (merosin)-deficient muscular dystrophy and demyelinating neuropathy in two cats (189) 37
O'Brien, M., see Kiebert, G.M. (191) 87
O'Brien, P.C., see Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials (189) 3
Ochi, H., see Horiuchi, I. (193) 49
Ochi, H., see Oishi, A. (193) 151
Ofuji, A., see Fujimoto, H. (187) 17
Oggero, A., see Durelli, L. (193) 17
Ohnuma, A., see Shimizu, H. (185) 39
Ohshita, T., see Naka, H. (193) 111
Ohyagi, Y., see Oishi, A. (193) 151
Oishi, A., Tobimatsu, S., Ochi, H., Ohyagi, Y., Kubota, T., Taniwaki, T., Yamamoto, T., Furuya, H. and Kira, J.-i.
Paradoxical lateralization of parasagittal spikes revealed by back averaging of EEG and MEG in a case with epilepsia partialis continua (193) 151
Ojanen, V., see Laatu, S. (185) 77
Oka, N., see Mizutani, K. (188) 9
Okamoto, K., see Hayashi, S. (188) 3
Okita, N., see Kikuchi, A. (193) 29
Okuda, B., Kawabata, K., Tachibana, H., Sugita, M. and Tanaka, H.
Postencephalitic pure anomic aphasia: 2-year follow-up (187) 99
Okuma, Y., see Noda, K. (188) 95

Ono, S., Hu, J., Shimizu, N., Imai, T. and Nakagawa, H.
Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis (187) 27
Onodera, Y., see Tateyama, M. (194) 29
Ooie, T., see Hashida, H. (190) 87
Øren, A., White, L.R. and Aasly, J.
Apoptosis in neurones exposed to cerebrospinal fluid from patients with multiple sclerosis or acute polyradiculoneuropathy (186) 31
Osame, M., see Nakagawa, M. (184) 15
Osame, M., see Nakagawa, M. (185) 31
Osame, M., see Matsuyama, W. (186) 75
Osborne, D., see Caselli, R.J. (189) 93
Oshio, C., see Ishikawa, M. (194) 59
Osoegawa, M., see Horiuchi, I. (193) 49
Ouchi, Y., see Miyajima, H. (184) 197

Padovani, A., see Monastero, R. (184) 33
Palmarini, M.F., see Di Carlo, A. (188) 85
Pandey, R.M., see Behari, M. (190) 49
Pandit, L., see Thomas, S.V. (188) 73
Pantoni, L., see Di Carlo, A. (188) 85
Papadimitriou, A., see Hadjigeorgiou, G.M. (194) 83
Papalia, A., see Vita, G. (186) 45
Pascual, M., see Fedetz, M. (190) 69
Pasquali, L., see Siciliano, G. (191) 61
Pastore, I., see Mazzini, L. (191) 139
Pastorini, E., see Siciliano, G. (191) 61
Patel, M., see Hajat, C. (190) 79
Paterakis, K., see Hadjigeorgiou, G.M. (194) 83
Pattee, G.L., see Ball, L.J. (191) 43
Pawelzik, T., see Manganotti, P. (184) 27
Pellecchia, M.T., see Perretti, A. (192) 35
Pels, H., see Pohl, C. (190) 21
Pençe, S., see Yilmaz, M. (184) 139
Pender, M.P., see Harness, J. (187) 7
Pera, J., see Szczudlik, A. (189) 105
Perna, A.M., see Di Carlo, A. (188) 85
Perozzo, P., Rizzone, M., Bergamasco, B., Castelli, L., Lanotte, M., Tavella, A., Torre, E. and Lopiano, L.
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation (192) 9
Perretti, A., Pellecchia, M.T., Lanzillo, B., Campanella, G. and Santoro, L.
Excitatory and inhibitory mechanisms in Wilson's disease: investigation with magnetic motor cortex stimulation (192) 35
Perunovic, B., Quilty, R.D., Athanasiou, A. and Love, S.
Damage to intracranial optic pathways in fatal closed head injury in man (185) 55
Pestronk, A., see Lopate, G. (188) 67
Peter, J.B., see Reiber, H. (184) 101
Piccini, C., see Di Carlo, A. (188) 85
Piccolo, G., see Franciotta, D. (190) 11
Pingree, M., see Greenlee, J.E. (184) 131
Pirulli, D., see Masè, G. (191) 11
Pisanello, A., see Guidetti, D. (184) 203
Pohl, C., Block, W., Träber, F., Schmidt, S., Pels, H., Grothe, C., Schild, H.H. and Klockgether, T.
Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients (190) 21
Polman, C.H., see Kalkers, N.F. (184) 155
Polman, C.H., see Kalkers, N.F. (187) 111
Polo, J.M., see Berciano, J. (194) 75
Porretto, F., see Caimi, G. (186) 23
Powell, H.C., see O'Brien, D.P. (189) 37
Pozzoli, U., see Montirosso, R. (194) 3
Pracucci, G., see Di Carlo, A. (188) 85
Pradat, P.F., see Spreux-Varoquaux, O. (193) 73
Prelle, A., see Bendotti, C. (191) 25
Press, R., Matá, S., Lolli, F., Zhu, J., Andersson, T. and Link, H.
Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain–Barré syndrome (190) 41
Preux, P.M., see Bisser, S. (193) 127
Prior, T.W., see Miller, R.G. (191) 127
Pruvo, J.P., see De Seze, J. (188) 37
Pugliatti, M., see Sotgiu, S. (190) 99

Quilty, R.D., see Perunovic, B. (185) 55

Rabey, J.M., see Kushnir, M. (186) 101
Rabinowitz, R., see Wang, N. (184) 183
Raju, T.R., see Shahani, N. (185) 109
Ramaekers, V.T., see Senderek, J. (192) 49
Rantalaiho, T., Färkkilä, M., Vaheri, A. and Koskiniemi, M.
Acute encephalitis from 1967 to 1991 (184) 169
Rao, S., see Nair, K.P.S. (187) 77
Rapalino, O., see Levine, D.N. (192) 1
Rapoport, S.I., see Hampel, H. (194) 15
Rasmussen, H.B., Kelly, M.A., Francis, D.A. and Clausen, J.
CTLA4 in multiple sclerosis. Lack of genetic association in a European Caucasian population but evidence of interaction with HLA-DR2 among Shanghai Chinese (184) 143
Ravizza, T., see Comoletti, D. (192) 61
Regidor, I., see Cid, C. (193) 103
Reiber, H. and Peter, J.B.
Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs (184) 101
Reichhart, M., see De Freitas, G.R. (193) 43
Reiman, E.M., see Caselli, R.J. (189) 93
Reis, A., see Grau, A.J. (192) 41
Rendell, M., Rizza, R.A., Service, F.J., Thomas, P.K., Walk, D., Wang, A.K., Wessel, K., Windebank, A.J., Ziegler, D. and Zochodne, D.W. (189) 3
Revonsuo, A., see Laatu, S. (185) 77
Rigby, S.A., see Lee, J.N. (191) 79
Ringel, S.P., see Sanjak, M. (191) 55
Rizza, R.A., see Rendell, M. (189) 3
Rizzato, B., see Diomedi, M. (185) 49
Rizzone, M., see Perozzo, P. (192) 9
Road, J., see Stewart, H. (191) 67
Robotti, M., see Sironi, M. (186) 51
Rocca, M.A., see Codella, M. (194) 71
Roccatagliata, L., see Mancardi, G. (184) 41
Rodolico, C., see Vita, G. (186) 45
Roelke, K., see Sanjak, M. (191) 55
Roh, J.-K., see Chu, K. (185) 27
Roldán, A.-N., see Aguilera, I. (192) 81
Rolfo, M., see Masè, G. (191) 11
Romani, A., see Bergamaschi, R. (189) 13
Rong, W., see Yu, K. (189) 23
Ros, S., see Masè, G. (191) 11
Rosati, G., see Sotgiu, S. (190) 99
Rosenfeld, J., see Jackson, C.E. (191) 75
Rovaris, M., see Inglese, M. (188) 33
Rovera, A., see Montalenti, E. (184) 65
Rowland, L.P., see Albert, S.M. (191) 115
Rudd, A.G., see Hajat, C. (190) 79
Rudi, J., see Grau, A.J. (186) 1
Rudnik-Schöneborn, S., see Senderek, J. (192) 49
Ruggieri, M., see Avolio, C. (186) 65

Russell, J.W., Gill, J.S., Sorenson, E.J., Schultz, D.A. and Windebank, A.J.
Suramin-induced neuropathy in an animal model (192) 71
Russman, B., see Miller, R.G. (191) 127
Ruutiainen, J., see Laatu, S. (185) 77

Sadamasa, H., see Noda, K. (188) 95
Saguer, M., see Kamada, K. (186) 13
Saint Michel, T., see De Seze, J. (188) 37
Sairanen, T.R., Lindsberg, P.J., Brenner, M., Carpén, O. and Sirén, A.-L.
Differential cellular expression of tumor necrosis factor-α and Type I tumor necrosis factor receptor after transient global forebrain ischemia (186) 87
Sakai, K., see Hagiwara, H. (193) 59
Sakakibara, R., Shinotoh, H., Uchiyama, T., Yoshiyama, M., Hattori, T. and Yamanishi, T.
SPECT imaging of the dopamine transporter with [^{123}I]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction (187) 55
Sakamoto, M., see Miyajima, H. (184) 197
Sakoe, K., see Namekawa, M. (185) 63
Sakoe, K., see Shimazaki, H. (185) 101
Sakoe, K., see Namekawa, M. (187) 103
Sakurai, A., see Hayashi, S. (188) 3
Sakurai, H., see Hanyu, H. (188) 79
Salachas, F., see Le Forestier, N. (185) 95
Salachas, F., see Spreux-Varoquaux, O. (193) 73
Saleem, Q., see Murgod, U.A. (190) 73
Salinas, M., see Cid, C. (193) 103
Samaha, F., see Miller, R.G. (191) 127
Samson, Y., see Le Forestier, N. (185) 95
Sangiovanni, V., see Di Carlo, A. (188) 85
Sani, G., see Di Carlo, A. (188) 85
Sanjak, M., Brinkmann, J., Belden, D.S., Roelke, K., Waclawik, A., Neville, H.E., Ringel, S.P., Murphy, J.R. and Brooks, B.R.
Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis (191) 55
Sansone, V., see Meola, G. (193) 89
Santens, P., see De Reuck, J. (193) 1
Santoro, L., see Perretti, A. (192) 35
Sarma, P.S., see Thomas, S.V. (188) 73
Sasaki, H., see Shimazaki, H. (185) 101
Sasaki, I., see Deguchi, K. (190) 61
Sastre Toraño, J., see Groeneveld, G.J. (191) 121
Sato, K., see Murakami, T. (189) 45
Sato, S., see Ishikawa, M. (194) 59
Satoh, J.-i. and Kuroda, Y.
A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population (189) 113
Saunders, A.M., see Caselli, R.J. (189) 93
Scarpini, C., see Mondelli, M. (190) 29
Schapiro, M.B., see Hampel, H. (194) 15
Scheltens, P., see Bokde, A.L.W. (194) 35
Schild, H.H., see Pohl, C. (190) 21
Schlesinger, F., see Krampfl, K. (191) 19
Schmidt, R.E., see Josephson, S.A. (188) 51
Schmidt, S., Wessels, L., Augustin, A. and Klockgether, T.
Patients with Multiple Sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation (187) 49
Schmidt, S., see Pohl, C. (190) 21
Schröder, J.M., see Sindern, E. (186) 81
Schröder, J.M., see Senderek, J. (192) 49
Schultz, D.A., see Russell, J.W. (192) 71
Schwartz, E.I., see Akhmedova, S.N. (184) 179
Schwarz, R., see Hampel, H. (194) 15
Schwarz, R., see Bokde, A.L.W. (194) 35
Sclaunich, F., see Montirosso, R. (194) 3
Scolding, N.J., see Hickman, S.J. (187) 35
Seah, A., see Tan, E.K. (190) 95
Sechi, G.P., see Sotgiu, S. (190) 99
Sekiguchi, Y., see Inaba, Y. (185) 89
Sekizuka, E., see Ishikawa, M. (194) 59
Senderek, J., Ramaekers, V.T., Zerres, K., Rudnik-Schöneborn, S., Schröder, J.M. and Bergmann, C.
Phenotypic variation of a novel nonsense mutation in the P0 intracellular domain (192) 49
Sepcic, J., see Masè, G. (191) 11
Service, F.J., see Rendell, M. (189) 3
Shahani, N., Gourie-Devi, M., Nalini, A. and Raju, T.R.
Cyclophosphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord (185) 109
Shaikh, Z.A., see Bakshi, R. (185) 19
Shannon, P., see Wong, A.M.F. (189) 71
Shanske, S., see Hadjigeorgiou, G.M. (194) 83
Sharpe, J.A., see Wong, A.M.F. (189) 71
Shekhar, L., see Thomas, S.V. (188) 73
Shelton, G.D., see O'Brien, D.P. (189) 37
Shi, Z., see Yu, K. (189) 23
Shibasaki, H., see Mizutani, K. (188) 9
Shiga, Y., see Shimizu, H. (185) 39
Shih, M.-C., see Tsai, C.-H. (190) 35
Shimazaki, H., Takiyama, Y., Sakoe, K., Amaike, M., Nagaki, H., Namekawa, M., Sasaki, H., Nakano, I. and Nishizawa, M.
Meiotic instability of the CAG repeats in the *SCA6 / CACNA1A* gene in two Japanese SCA6 families (185) 101
Shimazaki, H., see Namekawa, M. (185) 63
Shimazaki, R., Ueyama, H., Mori, T., Mori, M., Fujimoto, S., Kumamoto, T. and Tsuda, T.
Chronic sensory neuronopathy associated with human T-cell lymphotropic virus type I infection (194) 55
Shimizu, H., Shiga, Y., Fujihara, K., Ohnuma, A. and Itoyama, Y.
Clinical and physiological significance of abnormally prolonged central motor conduction time in HAM/TSP (185) 39
Shimizu, N., see Ono, S. (187) 27
Shindo, H., see Hanyu, H. (188) 79
Shinotoh, H., see Sakakibara, R. (187) 55
Shiozaki, K., Iseki, E., Hino, H. and Kosaka, K.
Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies—an immunohistochemical study (193) 23
Shoji, M., see Manabe, Y. (193) 13
Siciliano, G., Pastorini, E., Pasquali, L., Manca, M.L., Iudice, A. and Murri, L.
Impaired oxidative metabolism in exercising muscle from ALS patients (191) 61
Sicurelli, F., see Mondelli, M. (190) 29
Silani, V., see Bendotti, C. (191) 25
Silani, V., see Chiò, A. (191) 145
Silver, N.C., see Dehmeshki, J. (185) 11
Silver, N.C., see Hickman, S.J. (187) 35
Silvestrini, M., see Diomedi, M. (185) 49
Silvestris, F., see Avolio, C. (186) 65
Sima, A.A.F., see Zhang, W. (194) 21
Simpkins, J.W., see He, Z. (193) 79
Sindern, E., Schröder, J.M., Krismann, M. and Malin, J.P.
Inflammatory polyradiculoneuropathy with spinal cord involvement and letal outcome after hepatitis B vaccination (186) 81

Sirén, A.-L., see Sairanen, T.R. (186) 87
Sironi, M., Bardoni, A., Felisari, G., Cagliani, R., Robotti, M., Comi, G.P., Moggio, M. and Bresolin, N.
Transcriptional activation of the non-muscle, full-length dystrophin isoforms in Duchenne muscular dystrophy skeletal muscle (186) 51
Slowik, A., see Szczudlik, A. (189) 105
Slusher, B., see Zhang, W. (194) 21
SMA Study Group, see Miller, R.G. (191) 127
Smith, J., see Jackson, C.E. (191) 75
Smith, S., see Miller, R.G. (191) 127
Sobue, G., see Hattori, N. (184) 57
Sobue, G., see Yoshihara, T. (184) 149
Soong, B.-W., see Lo, H.-S. (194) 11
Sorenson, E.J., see Russell, J.W. (192) 71
Sotgiu, S., Pugliatti, M., Rosati, G. and Sechi, G.P.
Which syringomyelia is truly associated with multiple sclerosis? (190) 99
Spelle, L., see Le Forestier, N. (185) 95
Spreux-Varoquaux, O., Bensimon, G., Lacomblez, L., Salachas, F., Pradat, P.F., Le Forestier, N., Marouan, A., Dib, M. and Meininger, V.
Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients (193) 73
Srivastava, A.K., see Behari, M. (190) 49
Stanghellini, A., see Bisser, S. (193) 127
Stern, M.B., see Grossman, M. (184) 123
Stewart, H., Eisen, A., Road, J., Mezei, M. and Weber, M.
Electromyography of respiratory muscles in amyotrophic lateral sclerosis (191) 67
Stojkovic, T., see De Seze, J. (188) 37
Strijckmans, K., see De Reuck, J. (193) 1
Suehara, M., see Nakagawa, M. (184) 15
Sugamura, K., see Tateyama, M. (194) 29
Sugimoto, H., see Nemoto, H. (193) 7
Sugita, M., see Okuda, B. (187) 99
Sugiura, M., see Kikuchi, A. (193) 29
Sussman, A., see Mowzoon, N. (185) 119
Susuki, K., Yuki, N. and Hirata, K.
Fine specificity of anti-GQ1b IgG and clinical features (185) 5
Suzuki, H., see Miyajima, H. (184) 197
Suzuki, S., Kuwana, M., Yasuoka, H., Tanaka, K., Fukuuchi, Y. and Kawakami, Y.
Heterogeneous immunogenetic background in Japanese adults with myasthenia gravis (189) 59
Suzuki, T., see Hashida, H. (190) 87
Suzuki, Y., see Katayama, T. (193) 37
Szczudlik, A., Slowik, A., Turaj, W., Wyrwicz-Petkow, U., Pera, J., Dziedzic, T., Trabka-Janik, E. and Iskra, T.
Transient hyperglycemia in ischemic stroke patients (189) 105

Tabata, K.-i., see Matsuda, M. (184) 189
Tachibana, H., see Okuda, B. (187) 99
Tachiiri, Y., see Hashida, H. (190) 87
Taguchi, T., see Fujimoto, H. (187) 17
Takahashi, R., see Ishida, K. (188) 43
Takahashi, Y., see Miyajima, H. (184) 197
Takasaki, M., see Hanyu, H. (188) 79
Takase, S., see Kikuchi, A. (193) 29
Takashima, H., see Nakagawa, M. (184) 15
Takashima, H., see Nakagawa, M. (185) 31
Takeda, A., see Kikuchi, A. (193) 29
Takenaka, H., see Fukui, T. (184) 81
Takenouchi, N., see Nakagawa, M. (185) 31
Takeshima, T., see Nomura, T. (187) 41
Takeuchi, H., see Ishida, K. (188) 43
Takeuchi, H., see Deguchi, K. (190) 61
Takiguchi, M., see Tanaka, M. (188) 61
Takiyama, Y., see Namekawa, M. (185) 63
Takiyama, Y., see Shimazaki, H. (185) 101
Takiyama, Y., see Namekawa, M. (187) 103
Taly, A.B., see Nair, K.P.S. (187) 77
Tan, E.K., Chan, L.L. and Auchus, A.P.
Reversible parkinsonism in systemic lupus erythematosus (193) 53
Tan, E.K., Lo, Y.L., Seah, A. and Auchus, A.P.
Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis (190) 95
Tanaka, H., see Okuda, B. (187) 99
Tanaka, H., see Tomiyama, M. (189) 65
Tanaka, K., see Kametani, F. (188) 27
Tanaka, K., see Tanaka, M. (188) 61
Tanaka, K., see Suzuki, S. (189) 59
Tanaka, M., Tanaka, K., Tsuji, S., Kawata, A., Kojima, S., Kurokawa, T., Kira, J.-i. and Takiguchi, M.
Cytotoxic T cell activity against the peptide, AYRARALEL, from Yo protein of patients with the HLA A24 or B27 supertype and paraneoplastic cerebellar degeneration (188) 61
Tandan, R., see Bromberg, M.B. (184) 51
Taniwaki, T., see Oishi, A. (193) 151
Tateyama, M., Fujihara, K., Ishii, N., Sugamura, K., Onodera, Y. and Itoyama, Y.
Expression of OX40 in muscles of polymyositis and granulomatous myopathy (194) 29
Tavakoli, M. and Malek, M.
The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK (191) 95
Tavella, A., see Perozzo, P. (192) 9
Teichmann, E.M., see Urban, P.P. (186) 59
Teipel, S.J., see Hampel, H. (194) 15
Teipel, S.J., see Bokde, A.L.W. (194) 35
Terada, S., see Yokota, O. (194) 41
Terao, S., see Ishikawa, M. (194) 59
The Betaferon® Safety Trial (BEST) Study Group, see Durelli, L. (193) 17
Thiel, G., see Kaufmann, K. (189) 83
Thomas, P.K., see Rendell, M. (189) 3
Thomas, S.V., Sarma, P.S., Alexander, M., Pandit, L., Shekhar, L., Trivedi, C. and Vengamma, B.
Epilepsy care in six Indian cities: a multicenter study on management and service (188) 73
Thompson, A.J., see Dehmeshki, J. (185) 11
Thorne, R.G., see Liu, X.-F. (187) 91
Thornton, C.A., see Meola, G. (193) 89
Thornton, E.W., see Lee, J.N. (191) 79
Tian, S., see Wang, H. (194) 49
Tincani, A., see Monastero, R. (184) 33
Tobimatsu, S., see Oishi, A. (193) 151
Tofts, P.S., see Dehmeshki, J. (185) 11
Togo, T., Iseki, E., Marui, W., Akiyama, H., Uéda, K. and Kosaka, K.
Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies (184) 71
Tomiyama, M., Kimura, T., Maeda, T., Tanaka, H., Furusawa, K., Kurahashi, K. and Matsunaga, M.
Expression of metabotropic glutamate receptor mRNAs in the human spinal cord: implications for selective vulnerability of spinal motor neurons in amyotrophic lateral sclerosis (189) 65
Tomlinson, R.D., see Wong, A.M.F. (189) 71
Torre, E., see Perozzo, P. (192) 9
Touge, T., see Deguchi, K. (190) 61
Toyoda, K., Hirano, T., Kumai, Y., Fujii, K., Kiritoshi, S. and Ibayashi, S.
Bilateral deafness as a prodromal symptom of basilar artery occlusion (193) 147

Träber, F., see Pohl, C. (190) 21
Trabka-Janik, E., see Szczudlik, A. (189) 105
Trefoloni, G., see Di Carlo, A. (188) 85
Trivedi, C., see Thomas, S.V. (188) 73
Troiso, A., see Guidetti, D. (184) 203
Trojano, M., see Avolio, C. (186) 65
Tsai, C.-H., Jong, Y.-J., Hu, C.-J., Chen, C.-M., Shih, M.-C., Chang, C.-P. and Chang, J.-G.
Molecular analysis of SMN, NAIP and P44 genes of SMA patients and their families (190) 35
Tsuchiya, H., see Hashida, H. (190) 87
Tsuchiya, K., see Yokota, O. (194) 41
Tsuda, T., see Shimazaki, R. (194) 55
Tsuji, S., see Tanaka, M. (188) 61
Tsukada, K., see Ishikawa, M. (194) 59
Tsukaguchi, M., see Deguchi, K. (190) 61
Tsukamoto, T., see Zhang, W. (194) 21
Turaj, W., see Szczudlik, A. (189) 105

Uccelli, A., see Mancardi, G. (184) 41
Uchiyama, T., see Sakakibara, R. (187) 55
Uéda, K., see Togo, T. (184) 71
Uéda, K., see Iseki, E. (185) 129
Ueyama, H., see Shimazaki, R. (194) 55
Ugawa, Y., see Hagiwara, H. (193) 59
Ukkonen, M., see Luomala, M. (185) 123
Umehara, F., see Nakagawa, M. (185) 31
Umehara, F., see Matsuyama, W. (186) 75
Urban, P.P., Keilmann, A., Teichmann, E.M. and Hopf, H.C.
Sensory neuropathy of the trigeminal, glossopharyngeal, and vagal nerves in Sjögren's syndrome (186) 59
Usami, M., see Kametani, F. (188) 27

Vaheri, A., see Rantalaiho, T. (184) 169
Valois, N., see Grau, A.J. (192) 41
Van den Berg, L.H., see Groeneveld, G.J. (191) 121
Van Kan, H.J.M., see Groeneveld, G.J. (191) 121
Van Schijndel, R.A., see Kalkers, N.F. (184) 155
Van Schijndel, R.A., see Kalkers, N.F. (187) 111
Van Waesberghe, J.H.T.M., see Kalkers, N.F. (184) 155
Van Waesberghe, J.H.T.M., see Kalkers, N.F. (187) 111
Vedeler, C.A., see Aarskog, N.K. (188) 21
Veldink, J.H., see Groeneveld, G.J. (191) 121
Vengamma, B., see Thomas, S.V. (188) 73
Verdun, E., see Durelli, L. (193) 17
Vermersch, P., see De Seze, J. (188) 37
Vieth, J., see Kamada, K. (186) 13
Vignolo, L.A., see Monastero, R. (184) 33
Viskin, S., see Wang, N. (184) 183
Vita, G., Di Leo, R., De Gregorio, C., Papalia, A., Rodolico, C., Cogli-tore, S. and Messina, C.
Cardiovascular autonomic control in Becker muscular dystrophy (186) 45
V Lindeiner, H., see Eisensehr, I. (186) 7

Waclawik, A., see Sanjak, M. (191) 55
Walk, D., see Rendell, M. (189) 3
Wang, A.K., see Rendell, M. (189) 3
Wang, D., see Wang, H. (194) 49
Wang, H., Wang, Y., Wang, D., Cui, L., Tian, S. and Zhang, Y.
Cognitive impairment in Parkinson's disease revealed by event-related potential N270 (194) 49
Wang, L., see Chen, J. (189) 49
Wang, N., Chapman, J., Rabinowitz, R., Viskin, S., Kafri, M. and Korczyn, A.D.
Autonomic dysfunction in experimental autoimmune neuritis: Heart rate (184) 183
Wang, X.-Y., see Luomala, M. (185) 123
Wang, Y., see Wang, H. (194) 49
Warita, H., see Murakami, T. (189) 45
Warita, H., see Manabe, Y. (193) 13
Wasner, M., Klier, H. and Borasio, G.D.
The use of alternative medicine by patients with amyotrophic lateral sclerosis (191) 151
Wasner, M., see Neudert, C. (191) 103
Weber, M., see Stewart, H. (191) 67
Werle, E., see Grau, A.J. (192) 41
Wessel, K., see Rendell, M. (189) 3
Wessels, L., see Schmidt, S. (187) 49
White, L.R., see Øren, A. (186) 31
Willis, A., see Ball, L.J. (191) 43
Willison, H.J.
Fine specificity of anti-GQ1b antibodies and clinical features (185) 1
Wilson, D., see Winters, J.L. (188) 13
Windebank, A.J., see Rendell, M. (189) 3
Windebank, A.J., see Russell, J.W. (192) 71
Winters, J.L., Wilson, D. and Davis, D.G.
Congenital glioblastoma multiforme: a report of three cases and a review of the literature (188) 13
Wokke, J.H.J., see Groeneveld, G.J. (191) 121
Wolfe, C.D.A., see Hajat, C. (190) 79
Wolfes, H., see Krampfl, K. (191) 19
Wong, A.M.F., Musallam, S., Tomlinson, R.D., Shannon, P. and Sharpe, J.A.
Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates (189) 71
Woo, J.I., see Jhoo, J.H. (184) 21
Worms, P.M.
The epidemiology of motor neuron diseases: a review of recent studies (191) 3
Wozniak, K.M., see Zhang, W. (194) 21
Wrench, M., see Jackson, C.E. (191) 75
Wyrwicz-Petkow, U., see Szczudlik, A. (189) 105

Xue, M., see Del Bigio, M.R. (192) 53

Yahara, O., see Katayama, T. (193) 37
Yakimovsky, A.K., see Akhmedova, S.N. (184) 179
Yamada, M., see Ishida, K. (188) 43
Yamaguchi, N., see Ishikawa, M. (194) 59
Yamamoto, M., see Yoshihara, T. (184) 149
Yamamoto, T., see Oishi, A. (193) 151
Yamane, K., see Murakami, T. (189) 45
Yamanishi, T., see Sakakibara, R. (187) 55
Yamasoba, T., Kikuchi, S. and Higo, R.
Deafness associated with vertebrobasilar insufficiency (187) 69
Yan, H.-J., see Del Bigio, M.R. (192) 53
Yasuoka, H., see Suzuki, S. (189) 59
Yie, X., see Yu, K. (189) 23
Yılmaz, M., Erdal, M.E., Herken, H., Çataloluk, O., Barlas, Ö. and Bayazıt, Y.A.
Significance of serotonin transporter gene polymorphism in migraine (186) 27
Yilmaz, M., Bayazit, Y.A., Erbagci, I. and Pençe, S.
Visual evoked potential changes in migraine Influence of migraine attack and aura (184) 139
Yılmaz, M., see Erdal, M.E. (188) 99

Yokota, O., Ishizu, H., Terada, S., Tsuchiya, K., Haraguchi, T., Nose, S., Kawai, K., Ikeda, K. and Kuroda, S.
Preservation of nigral neurons in Pick's disease with Pick bodies: a clinicopathological and morphometric study of five autopsy cases (194) 41
Yonemura, H., see Fujimoto, H. (187) 17
Yoshida, T., Yoshino, A., Kobayashi, Y., Inoue, M., Kamakura, K. and Nomura, S.
Effects of slow repetitive transcranial magnetic stimulation on heart rate variability according to power spectrum analysis (184) 77
Yoshihara, T., Kanda, F., Yamamoto, M., Ishihara, H., Misu, K.-i., Hattori, N., Chihara, K. and Sobue, G.
A novel missense mutation in the early growth response 2 gene associated with late-onset Charcot–Marie–Tooth disease type 1 (184) 149
Yoshiike, T., see Noda, K. (188) 95
Yoshimura, K., see Ishida, K. (188) 43
Yoshino, A., see Yoshida, T. (184) 77
Yoshiyama, M., see Sakakibara, R. (187) 55
Youn, J.C., see Jhoo, J.H. (184) 21
Youn, J.Y., see Jhoo, J.H. (184) 21
Young, C.A., see Lee, J.N. (191) 79
Yu, K., Rong, W., Li, J., Jia, L., Yuan, W., Yie, X. and Shi, Z.
Neurophysiological evidence of spared upper motor conduction fibers in clinically complete spinal cord injury: discomplete SCI in rats (189) 23
Yuan, W., see Yu, K. (189) 23
Yue, J., see Lopate, G. (188) 67
Yuki, N., see Susuki, K. (185) 5

Zanconati, F., see Masè, G. (191) 11
Zanette, G., see Manganotti, P. (184) 27
Zebuhr, Y., see Bokde, A.L.W. (194) 35
Zerres, K., see Senderek, J. (192) 49
Zezlina, S., see Masè, G. (191) 11
Zhang, W., Slusher, B., Murakawa, Y., Wozniak, K.M., Tsukamoto, T., Jackson, P.F. and Sima, A.A.F.
GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats (194) 21
Zhang, X., see Chen, J. (189) 49
Zhang, Y., see Wang, H. (194) 49
Zhu, J., see Press, R. (190) 41
Ziegler, D., see Rendell, M. (189) 3
Zivadinov, R., see Zorzon, M. (187) 1
Zochodne, D.W., see Rendell, M. (189) 3
Zorzon, M., Zivadinov, R., Monti Bragadin, L., Moretti, R., De Masi, R., Nasuelli, D. and Cazzato, G.
Sexual dysfunction in multiple sclerosis: a 2-year follow-up study (187) 1
Zuccoli, G., see Guidetti, D. (184) 203

ELSEVIER

Journal of the Neurological Sciences 194 (2002) 107–113

Journal of the Neurological Sciences

www.elsevier.com/locate/jns

Cumulative Subject Index (2002) Volumes 184–194

AAC (191) 43
Aβ, Presenilin-1 (188) 27
Acetylcholine receptor (189) 59
Action potential (189) 7
Activated oxygens (194) 59
Acupuncture (191) 151
Acute (189) 105
Acute ischaemic stroke (186) 23
Acute polyradiculoneuropathy (186) 31
Adhesion (194) 59
Adult-onset spastic ataxia (194) 75
Age (192) 17
Ageing (192) 27
Age of onset (184) 57
Age-transformation (194) 15
Aging (189) 93, (191) 3
Alpha-2-macroglobulin (A2M) (184) 21
ALS (189) 45, (189) 65, (191) 11, (191) 19, (191) 61, (191) 95, (191) 111
Alternative splicing (191) 19
Alzheimer (188) 27
Alzheimer's disease (184) 81, (188) 79, (189) 93, (192) 27, (193) 23, (194) 15
Alzheimer's disease (AD) (184) 21
Ambulatory blood pressure monitoring (193) 13
4-Aminopyridine (189) 23
AMPA (192) 61
AMPA receptors (191) 19
Amyloid (188) 27
Amyloid precursor protein (184) 41
Amyotrophic lateral sclerosis (185) 95, (185) 109, (186) 37, (187) 27, (188) 3, (190) 17, (190) 21, (190) 95, (191) 3, (191) 25, (191) 35, (191) 55, (191) 67, (191) 75, (191) 87, (191) 103, (191) 115, (191) 121, (191) 133, (191) 139, (191) 145, (193) 117
Amyotrophic lateral sclerosis (ALS) (184) 51, (191) 79, (193) 73
Amyotrophy (184) 11
Anaerobic glycolysis (190) 3
Anatomical landmark (194) 35
Ancestor (185) 43
Anemic hypoxia (190) 3
Animal model (189) 37
Anterior inferior cerebellar artery (193) 147
Anti-AChR antibody (193) 59
Antibodies (190) 41
Antibody index (193) 127
Anti-GAD antibody (193) 59
Antiganglioside antibodies (188) 9
Anti-GQ1b IgG (185) 5
Anti-Hu antibodies (188) 61
Anti-Yo antibodies (188) 61
Anti-Yo antibody (185) 135
Apolipoprotein E (189) 93
Apolipoprotein E ε4 allele (190) 17
Apolipoprotein E (APOE) (184) 21
Apoptosis (186) 31, (192) 61
Astrocytes (185) 109
Atrophy (188) 79, (189) 99
Auditory brainstem response vertebrobasilar insufficiency (187) 69
Aura (184) 139
Autoantibodies (184) 131
Autoimmune disease (189) 59
Autoimmune diseases (184) 131
Autonomic nervous system (184) 77, (184) 183, (186) 45
Autopsy (184) 189
AXOKINE (192) 53
Axon (188) 67
Axonal (185) 31, (190) 41
Axonal damage (184) 41
Axonal injury (185) 55
Axonal neuropathy (184) 1
Axons (192) 71

Back disorders (192) 17
Basal ganglia (186) 107, (188) 95
Bayesian analysis (189) 13
Becker muscular dystrophy (186) 45
Behavioral tests (189) 49
Behçet's disease (188) 95
Bell's palsy (193) 97
Bidi smoking (190) 49
Bi-modal positive airway pressure (191) 75
Biological markers (191) 35
Bladder sensation (187) 77
Blood coagulation (185) 89
Blood–CSF barrier dysfunction (193) 127
Bone marrow stromal cell (189) 49
Botulinum toxin (190) 95
Brain (185) 19, (188) 13
Brain atrophy (184) 155
Brain ischaemia (185) 55
Brain lobes (194) 35
Brain neoplasms (188) 13
Brain oxygenation (190) 3
Brain plasticity (189) 49
Brain proteins in CSF (184) 101
Brainstem (193) 147
Brain trauma (185) 55
Brain tumor (186) 13
Breast neoplasms (184) 131

CADASIL (193) 13, (193) 43
CAG (185) 43
CAG repeat (190) 87
CAG repeats (185) 101
Calcarine cortex (188) 33
Cardiac arrhythmias (193) 89
Cardiac dysfunction (184) 183
Cardiovascular tests (186) 45
Carotid artery dissection (184) 203
Case report (188) 13

PII: S0022-510X(02)00012-6

Caspase-3 (193) 79
$CD4^+$ $CD45RO^+$ (186) 65
Central amygdaloid nucleus (185) 129
Central motor conduction (190) 21
Central motor conduction time (CMCT) (185) 39
Central nervous system (188) 95
Central sensory conduction time (CSCT) (185) 39
Cerebellar ataxia (187) 35, (187) 41
Cerebral blood flow (193) 79
Cerebral hemodynamics (190) 3
Cerebral infarction (193) 147
Cerebral ischemia, focal (187) 91
Cerebral venous thrombosis (185) 27
Cerebrospinal fluid (184) 101, (186) 75, (190) 99, (193) 103
Cerebrospinal fluid (CSF) (193) 73
Cerebrospinal fluid leak (192) 1
Cerebrotendinous xanthomatosis (190) 29
Cerebrovascular disease (190) 79
Cerebrovascular disorders (193) 43
Cerebrovascular reactivity (185) 49
Charcot–Marie–Tooth (188) 21
Charcot–Marie–Tooth disease (184) 1
Charcot–Marie–Tooth neuropathy type 1B (192) 49
Chenodeoxycholic acid (190) 29
Chinese (190) 35, (194) 11
Choreiform movements (187) 103
Choroid plexus (193) 137
Chromogranin-A (184) 71
Chronic infection (186) 1
Chronic inflammatory demyelinating polyneuropathy (184) 57, (185) 119, (193) 49
Chronic ischaemia (193) 1
CIO gene (192) 81
$[^{123}I]$-β-CIT (187) 55
Citrullinemia (193) 63
Classification (190) 79
Clinical features (184) 65
Clinical trial (191) 127
Clomipramine (184) 27
Closed head injury (185) 55
CMT2 (184) 1
CMT1 (184) 149
CMT1A (188) 21
CMT1B (192) 49
CMTX (185) 31
CNTF (192) 53
Cobalt-55 (193) 1
Cochlea (187) 69
Cochlear nuclei (187) 69
Cognitive disorders (185) 77
Cognitive impairment (184) 33, (188) 85
Cognitive slowing (194) 3
Color vision (186) 107
Complement (184) 71
Complement 4a (190) 11
Complementary therapies (191) 151
Complement 4b (190) 11
Complement factor B (190) 11
Complex I deficiency (192) 81
Compound heterozygotes (193) 63
Computer simulation (189) 71
Congenital (188) 13
Congenital muscular dystrophy (189) 37
Connexin 32 (185) 31
Constipation (185) 63
Coping strategies (191) 79
Corticosteroid (186) 75
Cost effectiveness (191) 95
Cost of epilepsy (188) 73
Cost utility (191) 95
Cramps (194) 83
Creatine supplementation (191) 139
Creutzfeldt–Jakob disease (184) 163
CSF (186) 31
CSF evaluation programs (184) 101
CSF immunoglobulins (184) 101
CTLA4 (184) 143
Culture neurons (193) 103
Cyclophosphamide (185) 109
Cyclosporin A (187) 7
CYP1A2 (191) 121
Cytokine (187) 27, (190) 69
Cytokines (186) 87, (187) 7, (187) 81
Cytotoxic T cells (188) 61

Deafness (187) 69
Deep brain stimulation (192) 9
Deep sensation (185) 5
Degeneration (193) 117
Deletion (185) 31
Delivery of care (188) 73
Dementia (184) 81, (188) 51
Dementia with Lewy bodies (184) 71, (185) 129, (193) 23
Demyelinating (185) 31
Demyelination (184) 41, (184) 189, (189) 37, (192) 71
De novo expansion (185) 101
Dentatorubral-pallidoluysian atrophy (190) 87
Depression (184) 27, (184) 33
Diagnosis (188) 79, (191) 3, (193) 43, (194) 15
Diagnostic classification (191) 43
Diagnostic errors (184) 65
Diaphragm (191) 67
Diffusion tensor imaging (188) 33, (194) 71
Diffusion-weighted magnetic resonance imaging (184) 163
Diffusion-weighted MRI (185) 27
Disability (185) 11
Disability evaluation (187) 35
Discomplete spinal cord injury (189) 23
Discriminant analysis (194) 15
Dissection (193) 147
Dopamine (184) 123, (186) 107
Dopamine transporter (187) 55
Drooling (191) 111
DRPLA (190) 87
Drug efficacy trials (184) 51
Drug metabolism (191) 121
Duchenne/Becker muscular dystrophy (186) 51
Dysarthria (191) 43
Dysferlin (184) 15
Dystrophin brain isoform (186) 51
Dystrophin Purkinje-cell isoform (186) 51

EAM (193) 7
ECG (184) 183
Echocardiography (193) 89
Ectopic expression (186) 51
EEG (184) 65, (190) 57
EGF (189) 83
EGR2 (184) 149
Egr-1 (189) 83
Elderly patient (184) 189
Electromyography (185) 95, (189) 7
Electron microscopy (193) 43
Electrophysiology (184) 51

Eleventh cranial nerve (184) 203
ELISA (188) 67
EMG (184) 51
Encephalitis (184) 169, (187) 99, (188) 95, (190) 57
Encephalomyelitis (187) 7
Endpoint measures (184) 51
Ependyma (193) 137
Epidemiology (184) 169, (188) 73, (191) 3, (191) 115
Epilepsia partialis continua (193) 151
Estrogens (185) 49
Ethnic backgrounds (189) 113
Etiology (184) 169
Event-related potential (194) 49
Event-related potential (ERP) (190) 61
Event-related potentials (ERPs) (194) 3
Evoked potentials (190) 29
Evoked spinal cord potential (187) 17
Excitotoxicity (189) 65, (191) 19, (191) 25
Exercise (191) 61
Experimental autoimmune encephalomyelitis (184) 41, (185) 89
Experimental autoimmune neuritis (184) 183
Experimental ischemia (186) 87
Extracellular signal-regulated protein kinase (189) 83

Facial nerve (193) 97
Familial ALS (189) 45
Familial hemifacial spasm (193) 97
Fasciculations (189) 7
Fastigial nucleus (189) 71
Fastigial oculomotor region (189) 71
Fatigue (191) 133, (191) 139, (194) 71
Feline (189) 37
Fibrillations (189) 7
Fibrin (185) 89
Fibrinolysis (185) 89
Fine specificity (185) 5
FK-506 (193) 7
Fluid-attenuated inversion recovery (FLAIR) (186) 37
Fluorescence microscope (194) 59
Follow-up studies (188) 85
Friedreich ataxia (194) 75
Frontal dysfunction (184) 81
Frontal lobe (189) 93, (190) 61
Frontotemporal dementia (194) 41
Functional assessments (190) 73
F wave (185) 39

GAA expansion (194) 75
Gabapentin (191) 127
Gadolinium enhancement (189) 99
Ganglionopathy (194) 55
Gangliosides (188) 9, (190) 41
Gastric carcinoma (185) 135
GCPII inhibition (194) 21
GD1b (185) 5
Gender (192) 17
Gene interaction (184) 143
Gene mutation (184) 197
Gene polymorphism (190) 69
Genetic heterogeneity (190) 11
Genetics (194) 11
Genetic susceptibility (184) 143
Glioblastoma (188) 13
Glioma (189) 83
Glossopharyngeal nerve (186) 59
Glutamate (193) 73, (193) 117, (194) 21
Glycolysis (184) 197
Granulomatous myopathy (194) 29
Graves' disease (184) 81
Grey matter (194) 71
Guillain–Barré syndrome (184) 183, (186) 31, (186) 81, (190) 41, (193) 49

HAM/TSP (194) 55
Haplotypes (190) 11
HB_SAg/anti-HB_SAg (186) 81
Headache (192) 1
Health-related quality of life (191) 87
Health status (191) 103
Hearing loss (193) 147
Heart rate (184) 183
Heart rate variability (184) 77, (186) 45
Heart surgery (188) 85
Helicobacter pylori (186) 1
Hematoma (192) 53
Hemifacial spasm (193) 97
Hepatitis B-vaccination (186) 81
Hereditary motor and sensory neuropathy (184) 1, (192) 49
Herpes simplex virus (184) 169
Hippocampus (188) 79, (194) 15
Histogram (185) 11
Histogram analysis (184) 155
Histology (193) 79
HLA (189) 59
HLA-DR2 (184) 143, (194) 29
HLA-DR3 antigen (190) 11
HMG-CoA reductase inhibitors (187) 81
H reflex (186) 101
5-HT2A receptor (188) 99
HTLV-I (194) 55
Human (188) 13, (193) 37
Human African trypanosomiasis (193) 127
Human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (185) 39
Huntington's disease (190) 73
Hydrochephalus (186) 75
Hydrostatic indifferent point (192) 1
Hyperalgesia (194) 21
Hypertension (193) 1
Hyperthyroidism (184) 81
Hypotension (193) 1

ICAM-1 (193) 7
IgG subclasses (184) 131
Ileus (185) 63
IL-2R (194) 29
IL-1 receptor antagonist (185) 123
Imaging techniques (191) 35
Immunocytochemistry (188) 67
Immunogenetics (189) 59
Immunohistochemistry (185) 129, (186) 87, (187) 27, (188) 3, (193) 23, (194) 29
Immunopathology (190) 69
Incidence (184) 169, (191) 115
Inclusion body myositis (185) 119
Infant (188) 13
Infection (190) 57
Inflammation (189) 99, (192) 41
Inflammatory cell (186) 75
Inflammatory myositis (187) 61
Influenza (187) 61
Influenza B virus (187) 61
In situ hybridization (186) 87, (189) 65
Insulin-like growth factor-I (187) 91

Interferon β-1a (186) 65
Interleukin-1 (185) 123
Interleukin-6 (187) 27, (190) 69
Interleukin-8 (192) 41
Interobserver agreement (190) 79
Intracerebral hemorrhage (190) 3
Intracranial hypotension (192) 1
Intraobserver agreement (190) 79
Intrathecal immunoglobulin synthesis (193) 127
Invasive thymoma (193) 59
Inverted dipper (193) 13
Involvement of the anterior horn (186) 81
Iron (185) 19
Ischemic stroke (186) 1, (189) 105, (192) 41
Istro-Rumanian (191) 11
IvIg (190) 41

Japanese (190) 57
Jerk-locked back averaging (193) 151
Juvenile myoclonic epilepsy (184) 65

Kainate (192) 61
Koreans (184) 21
Kufs' disease (188) 51

Lactate (191) 61
Lacunar infarct (187) 69
Laminin (189) 37
Large Japanese family (184) 15
Laser (190) 87
Latent variables (189) 13
Late-onset (184) 149
Leber's hereditary optic neuropathy (188) 33
Leukocyte (194) 59
Lewy body (184) 71
LFA-1 (186) 65
LGMD2B (184) 15
L-NAME (192) 61
Longitudinal study (187) 1
Loss of function effect (185) 31
Low back pain (192) 17
Lower cranial nerves (184) 203
Low penetrance (189) 45
Lumbar puncture (192) 1
Lumbar puncture headache (192) 1
Lung neoplasms (184) 131
Lysosome (192) 27

Macrophage (188) 3
Magnetic resonance imaging (184) 155, (184) 163, (184) 189, (186) 37, (187) 35, (187) 49, (189) 99, (193) 103, (193) 111, (194) 15, (194) 71
Magnetic resonance spectroscopy (186) 13, (191) 35
Magnetisation transfer ratio (MTR) (185) 11
Magnetization transfer imaging (188) 33, (193) 111, (194) 71
Magnetization transfer ratio (184) 155, (188) 79
Magnetoencephalography (193) 151
Magnetoencephalography, *N*-acetyl aspartate, Pathological activity (186) 13
Major histocompatibility complex (190) 11
Malignant lymphoma (188) 43
Management (191) 145
MAP kinase (189) 83
Markov models (191) 95
Maximal voluntary isometric contraction (191) 55
1.5-Mb duplication (188) 21
McArdle's disease (192) 81, (194) 83
Median nerve (187) 17
Medical/systemic disease (193) 17
Meiotic instability (185) 101
Memory (189) 93
Merosin (189) 37
mGluR (189) 65
Mice (187) 61
Microdissection (190) 87
Microelectrode (189) 23
Microsatellite marker (185) 43
Middle cerebral artery occlusion (187) 91, (189) 49
Migraine (184) 139, (186) 27, (188) 99
Minor cognitive impairment (194) 49
Missense mutation (189) 45
Mitochondria (191) 25, (191) 61, (192) 81
Mitochondrial encephalomyopathy (194) 3
Miyoshi myopathy (184) 15
Models of care (191) 145
Molecular mimicry (186) 81
Monocytes (192) 41
Mononeuritis multiplex (193) 49
Morphometric study (194) 41
Motor cortex (185) 95
Motor evoked potential (189) 23
Motor evoked potential (MEP) (185) 39
Motor evoked potentials (187) 41
Motor fatigue (191) 55
Motor neuron (184) 11, (191) 25, (192) 61, (193) 117
Motor neuron death (189) 65
Motor neuron disease (189) 65, (190) 17, (190) 21, (191) 151
Motor neuron diseases (191) 3
Motor neurone disease (191) 103, (191) 111
Motor neurone disease (MND) (191) 79
Motor neurons (185) 109
Motor speech disorders (191) 43
Motor units (189) 7
Mouse (193) 117
MPZ (192) 49
MRI (185) 19, (188) 37, (188) 95, (190) 57, (193) 53
Multiple regression (185) 11
Multiple sclerosis (184) 41, (184) 143, (184) 155, (184) 189, (185) 11, (185) 19, (185) 77, (185) 123, (186) 31, (186) 65, (187) 1, (187) 7, (187) 35, (187) 49, (188) 37, (189) 13, (189) 99, (190) 69, (190) 99, (193) 17, (193) 103, (194) 71
Multiple system atrophy (190) 61
Muscarinic acetylcholine receptor (193) 23
Muscle (194) 83
Muscle twitch (189) 7
Mutation (184) 149
M wave (185) 39
Myasthenia gravis (185) 119, (189) 59
Myasthenia gravis (MG) (193) 59
Mycophenolate (185) 119
Myelin (188) 67
Myelin-associated glycoprotein (188) 9, (188) 67
Myelin protein zero (184) 1, (192) 49
Myelopathy (184) 11
Myeloradiculoneuritis (186) 81
Myoglobinuria (194) 83
Myophosphorylase gene (194) 83
Myosin (193) 7
Myositis (187) 61
Myotonic dystrophies (193) 89
Myotonic dystrophy (193) 111
Myotonic dystrophy type 1 (DM1) (193) 89

N13 (187) 17
N2 (194) 3

N270 (194) 49
NAAG (194) 21
NAIP (190) 35
Naming deficit (187) 99
Natural history (189) 13
Needle electromyography (191) 67
Neonatal rats (185) 109
Neopterin (192) 41
Nerve conduction (194) 21
Nerve conduction velocities (190) 29
Nerve conduction velocity (184) 183
Nerve growth factor (189) 49
Neurodegeneration (190) 49
Neurodegenerative disease (185) 95
Neurofilament-light gene (184) 1
Neuroimmunology (184) 101
Neurological deficits (187) 91
Neurological diseases (184) 101
Neurological services (188) 73
Neuromuscular disease (189) 7
Neuronal apoptosis (193) 103
Neuronal ceroid-lipofuscinoses (188) 51
Neurones (186) 31
Neuropathology (186) 81, (189) 71
Neuropathy (188) 67, (192) 71, (194) 21
Neuroprotection (187) 81, (187) 91
Neuropsychiatric SLE (184) 33
Neuropsychological examination (188) 85
Neuropsychology (184) 33, (185) 77, (192) 9
NF-κB (184) 71
NIRCA (184) 149
Nitric oxide (187) 81
NMDA (192) 61
NO (192) 61
Nocturnal hypoventilation (191) 75
Non-dipper (193) 13
Non-human primates (184) 41
Non-invasive positive pressure ventilation (191) 67, (191) 75
Non-permissive infection (187) 61
Nonsense mutation (184) 15, (194) 83
Normal-appearing white matter (193) 111
NOS (194) 11
Notch3 gene (193) 43
Novel insertion mutation (185) 63
Novelty P3 (190) 61

Obesity (192) 17
Object recognition (185) 77
Oculography (189) 71
Onset (184) 21
Opsoclonus (184) 131, (189) 71
Optic pathways (185) 55
Optic radiation (185) 55
Optic radiations (188) 33
Optic tract (185) 55
Organophosphates (184) 179
Orthostatic headache (192) 1
Orthostatic hypotension (190) 61
Ovarian neoplasms (184) 131
OX40 (194) 29
β-Oxidation (184) 197
Oxidative phosphorylation (184) 197
Oxymetholone (185) 27

P44 (190) 35
P0 (192) 49
P3 (194) 3
P300 (194) 49
Palliative care (191) 151
Paradoxical lateralization (193) 151
Paraneoplastic cerebellar degeneration (184) 131, (185) 135, (188) 61
Paraneoplastic disorders (184) 131
Paraneoplastic encephalomyeloneuritis (184) 131
Paraneoplastic neurological syndromes (188) 61
Paraneoplastic syndrome (189) 71
Paraoxonase (184) 179
Parasagittal epileptic discharges (193) 151
Parkinsonism (193) 53, (194) 41
Parkinson's disease (184) 123, (184) 179, (186) 7, (186) 101, (187) 55, (190) 49, (192) 9, (193) 29, (194) 11, (194) 49
Patch-clamp (191) 19
Pathology (188) 3, (188) 13, (194) 21
Pathophysiology (192) 1
Patient decision-making (191) 115
PC12D (188) 27
PCR-RFLP analysis (189) 113
PDGF (189) 83
PEG (191) 115
Peripheral blood T-lymphocytes (186) 65
Peripheral nerve (188) 67
Peripheral neuropathy (188) 43, (189) 37
Periphlebitis retinae (187) 49
PET (185) 95
Pets exposure (190) 49
Phenotype–genotype correlations (184) 1
Phenotypic variation (184) 15
Photostimulated luminescence imaging (188) 21
Photothrombus (194) 59
Physical activity (191) 133
Physical exercise (191) 133
Pick body (194) 41
Pick's disease (194) 41
Placebo-controlled trial (191) 127
Platelet (194) 59
Polymerase chain reaction (187) 7, (187) 61
Polymorphism (188) 99, (189) 113, (191) 121, (194) 11
Polymorphonuclear leukocyte (186) 23
Polymorphonuclear leukocyte activation (186) 23
Polymorphonuclear leukocyte integrins (186) 23
Polymyositis (185) 119, (194) 29
Polysomnography (186) 7
Positron emission tomography (184) 197, (191) 35, (193) 1
Posterior cranial fossa (187) 35
Post-polio syndrome (184) 11
Power spectral analysis (186) 45
P0 protein (188) 43
Preclinical (189) 93
Predictive variables (188) 85
Pre-movement facilitation (187) 41
Pretangle neuron (192) 27
Primary lateral sclerosis (185) 95
Primary progressive (185) 11, (186) 31
Principal component (185) 11
Prion protein disease (184) 163
Prion protein mutation (184) 163
Proestrus estradiol (193) 79
Prognosis (189) 105, (193) 89
Prognostic factors (189) 13
Proton magnetic resonance spectroscopy (190) 21
Proximal myotonic myopathy (193) 89
Psychotic symptom (185) 129
Pulmonary function studies (191) 75
Pulmonary function tests (191) 67
Pupillary disturbances (188) 37

Pure anomic aphasia (187) 99
Pure hereditary spastic paraplegia (185) 63
Pyramidal signs (186) 101

Quality of life (191) 79, (191) 103, (191) 111
Quality-of-life (191) 133

Radicular syndromes (192) 17
Randomized trial (191) 127
Rat (186) 87, (189) 23, (193) 137
Rats (184) 183, (193) 79
Reaction time (187) 41, (194) 3
Reciprocal inhibition (186) 101
Recombinant expression (191) 19
Recovery (184) 57
Regional segmentation (194) 35
Relapsing-remitting (186) 31
REM sleep behavior disorder (186) 7
Respiratory failure (191) 75
Respiratory muscles (191) 67
Reverse immunogenetics (188) 61
Riluzole (191) 95, (191) 121
Risk (184) 21
Risk factor (186) 1
Risk factors (190) 49, (192) 17
ROC analysis (194) 15
Rural living (190) 49

SCA6 (185) 43
Scale development (191) 79
Search coils (189) 71
γ-Secretase (188) 27
Secular trends (191) 3
SEIQoL-DW (191) 103
Seizures (190) 57
Sensorimotor demyelinating neuropathy (188) 9
Sensory neuronopathy (194) 55
Sensory neuropathy (186) 59
Sentence comprehension (184) 123
SEPs (185) 95
Serotonin (188) 99
Serotonin transporter gene (186) 27
Serum (187) 27
Sexual function (187) 1
SF-36 (191) 103
SGPG (188) 67
Sialorrhoea (190) 95
Signal transduction (189) 83
Single neuron (190) 87
Single-photon emission computed tomography (SPECT) (187) 55, (193) 29
SIP (191) 103
SJL/J mice (193) 7
Sjögren's syndrome (186) 59, (194) 55
Skeletal muscle (186) 51
Skin (187) 27
Skin biopsy (193) 43
SLC25A13 gene (193) 63
SMA (190) 35
SMN (190) 35
Smoking (192) 17
SNP (190) 69
SOD1 gene (191) 11
Sodium suramin (192) 71
Soluble ICAM-1 (186) 65
Somatic mosaicism (190) 87
Somatosensory (190) 61
Somatosensory evoked potential (187) 17
Somato-sensory-evoked potentials (187) 77
Somatosensory evoked potential (SEP) (185) 39
Southern blot (188) 21
Spasticity (191) 133
SPECT (184) 81
SPG4 gene (185) 63
Spheroid (185) 129
Sphingolipids (192) 71
Spinal cord (187) 17, (187) 77, (188) 3
Spinal muscular atrophy (191) 127
Spinocerebellar ataxia type 6 (SCA6) (185) 101
Spinocerebellar ataxia type 1 (SCA1) (187) 103
Spongy change (185) 129
Sporadic Parkinson's disease (189) 113
S1–S2 paradigm (194) 49
Stage determination (193) 127
Statins (187) 81
Statistical parametric mapping (193) 29
Steinert's disease (193) 89
Stiff-person syndrome (193) 59
Strength (191) 139
Stroke (185) 49, (187) 81, (193) 137
Subependyma (193) 137
Substantia nigra (185) 129, (194) 41
Subthalamic nucleus (192) 9
Subtype-specific antibody (193) 23
Subunit (191) 19
Superoxide dismutase 1 mutants (191) 25
Superoxide dismutase 1 (SOD1) (189) 45
Sural nerve (194) 55
Surface electromyogram (187) 103
Surrogate response (189) 13
Susceptibility, severity, gender (185) 123
Sweet's syndrome (188) 95
Sympathetic nervous system (187) 77
Sympathetic skin response (187) 77
α-Synuclein (184) 71
Syringomyelia (184) 189, (190) 99
Systemic lupus erythematosus (184) 33
Systemic lupus erythematosus (193) 53

Tangle (192) 27
TCD (185) 49
Temporal cortex (187) 99
Tentorial subdural hematoma (185) 27
Terminal care (191) 111
Therapy (185) 119
Thrombin–antithrombin III complex (185) 89
Th1/Th2 balance (193) 49
Thymectomy (189) 59, (193) 59
T1 hypointense lesions (193) 103
Thyroid autoantibodies (193) 17
Thyroid function (193) 17
Tissue factor (192) 41
TNF-α (186) 87
Tongue (193) 37
Tourette (186) 107
Tracheostomy (191) 115
Transcranial magnetic electric cortical stimulation (192) 35
Transcranial magnetic stimulation (184) 27, (184) 77, (187) 41, (190) 21, (193) 37
Transgenic mice (191) 25
Transient global ischemia (193) 79
Transient hyperglycemia (189) 105

Transplantation (189) 49
Transporter (193) 117
Treatment (184) 27, (191) 121
Trifunctional protein deficiency (184) 197
Trigeminal nerve (186) 59
Triplet repeat (190) 87
Triplet repeats (190) 73
Trypanosoma brucei gambiense (193) 127
T2 shortening (185) 19
Tumour necrosis factor-beta (190) 11
Twelfth cranial nerve (184) 203

Ubiquitin (192) 27
Ubiquitin carboxy-terminal hydrolase-L1 (189) 113
Upper motor neuron (186) 37, (190) 21
Urinary dysfunction (187) 55
Utilities (191) 87
Uveitis (187) 49

Vagal nerve (186) 59
Varicella-zoster virus (184) 169
Vascular dementia (193) 1
Vascular endothelial growth factor (186) 75
pVAW409R3a (188) 21
Venous dilation (192) 1
VEPs (185) 95
Visual evoked potential (184) 139
Visual processing (185) 77
Voluntary movements (187) 41

White matter changes (193) 1
White matter hyperintensities (194) 35
White matter lesions (193) 111
Wilson's disease (192) 35
Work-related and non-occupational strain (192) 17

Yo antigen (185) 135